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Abstract 
The clinical management of breast cancer patients is complicated by the high genetic 
heterogeneity of this disease, which makes the standardization of treatments, the prediction 
of prognosis and therapy response, and the development of personalized therapies difficult. 
Nevertheless, the advent of high-throughput genomics screenings based on microarray or 
next-generation sequencing (NGS) technologies has greatly enhanced our understanding of 
the genomic landscapes underlying breast cancer development and progression. Such 
discoveries are now allowing clinicians to tailor therapies based on the molecular subtype 
of the tumour (luminal, basal and HER2).  
NGS studies have also started to provide insights into the range of molecular 
profiles of tumour cells from the same tumour, and have shown that in some breast cancers 
a high level of intratumoral genetic heterogeneity exists. The findings from these studies 
support a scenario in which breast tumours can be either: i) monogenomic, comprised of a 
single clonal cell population; ii) or polygenomic, composed of several related clonal 
subpopulations. The co-existence of different cancer driver genetic lesions in polygenomic 
tumours might contribute to treatment failure in some cases, as relapse could be driven by 
the expansion of a subpopulation of cells intrinsically resistant to the therapy. Importantly, 
cancer genetic heterogeneity has been recapitulated in experimental settings using cancer 
stem cells (CSCs) xenografted in mouse models.  
We hypothesized that the mutational events that drive the onset and progression of 
breast tumours lie within the CSC compartment. To explore this possibility, we analysed 
and compared the mutational profiles of a primary breast tumour and its matched 
mammospheres (source of CSC-derived population), patient-derived xenograft (PDX) and 
PDX-derived mammospheres using Whole Exome Sequencing (WES).  
We setup a NGS approach to look for rare mutations in the primary tumour that 
may be present in the CSC compartment using low amounts of DNA input. We optimised 
an experimental protocol in which the genomic DNA (gDNA) of each sample was 
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subjected to Whole Genome Amplification (WGA) prior to performing WES. This enabled 
us to obtain a sufficient amount of DNA (≥ 3 µg) to perform WES. We also introduced a 
filtering step in our analysis, based on the Xenome software, for PDX-derived samples to 
eliminate possible contamination from murine DNA.  
Our study allowed us to characterize the genetic profiles of CSCs and to identify 
cancer-relevant mutations that could drive breast cancer onset and progression. We 
identified 15 candidate driver mutations in 11 genes that were enriched, in terms of 
mutation frequency, within primary tumour-derived mammospheres and the PDX. 
Together with these mutations, we identified 4 mutations in 4 genes, not enriched, but 
shared among all analysed samples, which likely represent “founder” mutations. 
Based on our results, we will now endeavour to determine the clinical relevance of 
the candidate driver mutations identified in our study by determining their prevalence in 
independent patient cohorts. Having optimised the protocol for NGS of matched primary 
tumour, PDX and mammosphere populations, we will also extend our mutational analysis 
to additional breast tumours for the identification of more driver mutations and for the 
deconvolution of intratumoral genetic heterogeneity of breast cancer. 
Understanding the driving mutational forces of breast tumours and relative 
mechanisms involved is paramount for the development of more effective therapeutic 
strategies. 
 
	 10	
Introduction 
1. Breast Cancer 
1.1 Epidemiology 
Breast cancer is the second most frequent cancer type worldwide and the first among 
women (Ferlay et al., 2015). Approximately 250,000 new cases are expected in 2016 in the 
United States alone (Siegel et al., 2016) (Figure 1). Prognosis of breast cancer largely 
depends on the tumour stage at diagnosis, i.e. from 26% of survival at 5 years for patients 
with distant metastases to 99% for patients with localized disease (Siegel et al., 2016). 
Therefore, breast cancer screening programs (i.e., mammography screening) are paramount 
for reducing disease burden by augmenting early diagnoses; indeed, mammography 
screening has been shown to be effective in reducing breast cancer mortality in large 
randomized screening studies (Gill et al., 2004; Joensuu et al., 2004). However, when a 
patient presents with advanced disease the chances of a curative treatment decrease due to 
the frequent propensity of breast cancer to become metastatic and chemoresistant.  
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Figure 1. Estimated New Cancer Cases and Deaths by Sex, United States, 2016. Taken from 
Siegel et al., 2016. 
 
1.2. Carcinogenesis 
Breast cancer like other types of tumours evolves from a normal cell that acquires genetic 
and epigenetic changes which confer it an advantage in terms of survival, proliferation, 
migration, and adaptation to different environmental conditions (e.g. different tissues, 
resistance to cytotoxic agents, etc.). These modifications, together with microenvironment 
variations determine the establishment of cell clones with the ability to grow and 
proliferate in an uncontrolled way. Importantly, during tumour initiation and progression 
the acquirement of chromosomal (Navin et al., 2011) and genomic instability has been 
observed, which frequently result from the inactivation of signalling pathways involved in 
the maintenance of chromosomes and genome integrity (i.e. loss of p53/p21, BRCA1-2, 
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etc.). Genomic and chromosomal instability have been shown to confer tumour cells with 
an increased potential to acquire alterations, such as DNA mutations, amplification, 
translocations, and aneuploidy, which ultimately contribute to progression to a metastatic 
and incurable disease. In addition, loss of heterozygosity and changes in gene copy number 
were also shown to increase the transition from hyperplasia to ductal carcinoma in situ 
(DCIS) which is the first step during tumour progression (O’Connell et al., 1998). 
Many of these alterations ultimately affect key genes (oncogenes and tumour 
suppressors) involved in cell survival, proliferation, invasiveness, motility and drug 
resistance (Sherr, 2004; Summy and Gallick, 2003). For example, the ERBB2, MYC, 
CCND1 and PI3KCA oncogenes are typically deregulated in breast cancer. The ERBB2 
gene encodes for a receptor tyrosine kinase that is a member of the epidermal growth 
factor (EGFR) family. When ERBB2 heterodimerizes with other EGFR family members, it 
mediates the activation of downstream pathways, such as mitogen-activated protein (MAP) 
kinase and phosphatidylinositol-3 kinase (PI3K)/Akt. ERBB2 is found to be amplified in 
~20% of breast cancer patients (Zhou et al., 1987). The MYC oncogene encodes for a 
nuclear phosphoprotein that acts as a transcription factor; it regulates targets specific for 
cell cycle progression, apoptosis and cellular transformation, and is overexpressed in ~20% 
of breast cancers (Nass and Dickson, 1997). The CCND1 gene encodes for the Cyclin D1 
protein, which is involved in G1-S phase transition during the cell cycle; it is amplified in 
~15% of breast cancer cases (Sutherland and Musgrove, 2004) and at high level seems to 
be associated with an oestrogen receptor (ER)-positive and increased Ki67 levels (Loden et 
al., 2002). The PI3KCA gene encodes for the catalytic subunit of the PI3K, it is mutated in 
~35% of breast cancers (Li et al., 2006). 
Other genes with a tumour suppressor function are commonly altered in breast 
cancer, e.g.: TP53, BRCA1, BRCA2 and PTEN. TP53 gene encodes for the transcription 
factor p53, which target genes are involved in cell cycle arrest, DNA repair, apoptosis and 
senescence. It is mutated in ~20% of breast cancers (Pharoah et al., 1999), and, when it is 
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not mutated, other mechanisms are in place to inactivate p53 function in breast cancer. For 
example, alterations in upstream regulators of p53 (ATM and CHEK2), in p53 co-activators 
(ASPP1, ASPP2 and BRCA1) and in p53 target genes (SIGMA, MDM2 and CDKN1A) have 
been detected in breast cancer (Gasco et al., 2002). BRCA1 “breast cancer 1 early-onset” 
and BRCA2 “breast cancer 2 early-onset” are breast cancer susceptibility genes encoding 
for nuclear phosphoproteins. BRCA1 and BRCA2 genes are mutated in 3-8% of patients 
affected by breast cancer screened by The Cancer Genome Atlas (TCGA) consortium 
(http://www.cbioportal.org/). At least 50% of women who inherit a BRCA1 mutation and 
around 45% of women who inherit a BRCA2 mutation will develop breast cancer by the 
age of 70 years (Antoniou et al., 2003; Chen and Parmigiani, 2007). The PTEN gene 
encodes for a tumour suppressor phosphatase and is mutated in <5% of breast cancer 
patients (Lu et al., 1999). Loss of heterozygosity of PTEN locus at chromosome 10q23 
occurs in 10-40% of breast cancers (Bose et al., 1998). 
Beyond these genetic alterations of cancer-related genes, epigenetic changes 
including hypo- and hyper-methylation of gene promoter regions, histone tail 
modifications, and nucleosome remodelling, have been shown to be relevant for breast 
cancer onset and progression. For example, it has been shown that only a few genes are 
hypomethylated in breast cancer (e.g., FEN1, NAT1 and CDH3) (Singh et al., 2008; Kim et 
al., 2008; Paredes et al., 2005), while the majority (>1000) of genes were reported to be 
hypermethylated (Hinshelwood and Clark, 2008). Among them, BRCA1 was found 
hypermethylated in sporadic breast cancer (Chan et al., 2002) and CDKN2A has been 
described to have aberrant CpG island methylation (Herman et al., 1995). Although several 
studies have been performed to map molecular alterations responsible for breast cancer 
initiation and progression (Ma et al., 2003; Moinfar et al., 2000; Stephens et al., 2012), a 
complete picture of the pathogenic events is still lacking, which limits therapeutic options, 
particularly, for those patients with advanced stage disease. 
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1.3. Classification 
Breast cancer can be classified into different subtypes based on histopathological, 
molecular and functional features:  
1.3.1. Histopathological Classification 
The most frequent breast cancer subtype is breast adenocarcinoma (~95%), with the 
remaining cases made up of breast sarcomas and mixed-type breast cancers (Schuur and 
DeAndrade, 2015). Breast adenocarcinoma can be further categorized into: i) ductal 
carcinoma in situ (DCIS), which grows within the milk duct; ii) lobular carcinoma in situ 
(LCIS), which grows outside the duct within the breast; iii) invasive ductal carcinoma 
(IDC), which grows within the duct and invades the surrounding tissue in a random 
manner; iv) invasive lobular carcinoma (ILC), which arises within the end part of the 
lobule and infiltrates the mammary stroma and adipose tissue in a single-file pattern.  
Invasive carcinomas, both IDCs and ILCs, are a heterogeneous group of tumours 
consisting of different histological subtypes. IDC (Figure 2) is the most common subtype 
accounting for ~80% of all invasive lesions. IDC is further sub-classified as either well 
differentiated (grade 1), moderately differentiated (grade 2) or poorly differentiated (grade 
3) based on the levels of nuclear pleomorphism, glandular/tubule formation and mitotic 
index (Elston and Ellis, 1991). 
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Figure 2. Infiltrating ductal breast carcinoma. Haematoxylin and eosin staining of an infiltrating 
ductal carcinoma in breast tissue (right side of the panel, blue arrows) with an in situ component 
(left side of the panel, red arrows). Taken from IEO archival collection of tumour samples. 
 
Tumour stage is another important clinical and pathological characteristic used to 
determine treatment options for breast cancer patients. Tumour stage is defined by the 
TNM system (Figure 3) based on size of the tumour (T), lymph node spread (N) and 
metastatic dissemination (M). Briefly, the main stages are as follow:  
• Stage 0, pre-cancerous condition. 
• Stage 1-3, tumour is within the breast and the lymph nodes. 
• Stage 4, tumour is already metastatic. 
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Figure 3. Breast Cancer Staging. TNM staging system. Adapted from American Joint 
Committee on Cancer, 7th Edition. Briefly, T refers to primary tumour characteristic: Tis carcinoma 
in situ, T1 Tumour ≤ 20 mm in greatest dimension; T2 Tumour > 20 mm but ≤ 50 mm in greatest 
dimension; T3 Tumour > 50 mm in greatest dimension; T4 Tumour of any size with direct 
extension to the chest wall and/or to the skin (ulceration or skin nodules). N refers to lymph node 
metastatization: N0, No regional lymph node metastases; N1, Metastases to movable axillary 
lymph node(s); N2, Metastases in axillary lymph nodes that are clinically fixed or matted, or in 
clinically-detected internal mammary nodes in the absence of clinically evident axillary lymph 
node metastases; N3 Metastases in infraclavicular lymph node(s), or in clinically-detected internal 
mammary lymph node(s) with clinically evident axillary lymph node metastases, or metastases in 
supraclavicular lymph node(s) with or without axillary or internal mammary lymph node 
involvement. M refers to distant metastasis presence: M0, No clinical or radiographic evidence of 
distant metastases; M1, Distant detectable metastases larger than 0.2 mm. * Include T1mi, Tumour 
≤ 1 mm in greatest dimension; ** T0 and T1 tumours with nodal micrometastases only are 
excluded from Stage IIA and are classified Stage IB. 
 
1.3.2. Molecular Classification 
The identification of peculiar molecular characteristics through microarray analysis led to 
the classification of breast cancer into distinct molecular subtypes. In particular, the 
PAM50 study posed the basis for this classification (Parker et al., 2009) and proposed to 
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classify breast cancer into basal-like (also known as triple negative, TN), HER2, luminal A, 
and luminal B subtypes. Basal-like/TN breast cancers are negative for three common 
immunohistological markers: the ER, the progesterone receptor (PR), and HER2. This 
subtype of breast cancer accounts for 15-20% of all breast tumours and is the most 
aggressive tumour subtype, associated with a poor prognosis. The HER2 subtype refers to 
tumours harbouring ERBB2 amplification but negative for ER and PR. These tumours are 
usually poorly differentiated (high-grade) and account for 15% of total tumours. Luminal 
A tumours are ER-positive and/or PR-positive, and HER2-negative with a low 
proliferation index characterized by a low percentage of Ki67 (a proliferation antigen) 
positive cells (i.e. with a Ki67<14%). They are low-grade tumours (1 or 2) and are 
associated with a more favourable prognosis. Finally, luminal B tumours are ER-positive 
and/or PR-positive, with a Ki67≥14%, or even with a Ki67<14% but HER2-positive. 
These tumours tend to be poorly differentiated and associated with a poorer prognosis 
compared with luminal A tumours (Coates et al., 2015). 
 
1.3.3. Functional Classification 
Histopathological analyses, and recently also molecular tests, are routinely used to 
characterize and molecularly categorize breast tumours in order to define the optimal 
therapeutic strategy to treat patients. However, the identification of curative treatments for 
more advanced breast cancer is still an unmet clinical need, which will require a deeper 
understanding of breast tumour biology and the mechanisms of progression and 
metastatization.  
In 2003, Clarke and colleagues first identified tumorigenic breast cancer cells with 
stem cell characteristics (Al-Hajj et al., 2003). The isolation of tumour-initiating cells with 
stem cell-like characteristics should allow the identification of specific molecular 
alterations that can be used to tailor targeted therapies to eradicate the disease. Currently, 
there are different cell markers that could be used to isolate breast CSCs for further 
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characterization. In particular, CD44/CD24 (Al-Hajj et al., 2003), CD49f/CD29 (Lim et al., 
2009) and ALDH1 (Ginestier et al., 2007) are the markers most commonly used to identify 
and isolate both normal and cancer breast stem cells. CD44, CD24, CD49 and CD29 are 
surface proteins, while ALDH1 is an intracellular enzyme. The CD44 gene encodes for a 
cell surface glycoprotein involved in cell-cell interactions, cell migration and tumour 
growth and progression (Alves et al., 2008; Dang et al., 2015; McFarlane et al., 2015). The 
CD24 surface protein is expressed in B lymphocytes and differentiated neuroblasts, and 
modulates growth and differentiation signals (Rostoker et al., 2015). The CD49f gene 
encodes for the alpha-6/beta-4 integrin that interacts with the extracellular matrix and 
stimulates invasion through the EGFR signalling pathway (Carpenter et al., 2015). The 
CD29 protein is encoded by the ITGB1 gene and it is an integrin beta subunit. CD29 is 
involved in cell-cell and cell-extracellular matrix interactions, in signal transduction, and in 
endothelial-to-mesenchymal transformation (Shi et al., 2015). 
 
1.4. Diagnosis 
Many efforts have been made to diagnose breast cancer early in order to increase survival 
of patients and prevent metastatic spread. Typical tools for diagnosis are mammography, 
echography and magnetic resonance imaging. After the identification of atypical masses 
through imaging technology, a biopsy is made to understand the nature of the recognized 
lesion and characterize it. Recent results of more than 20 years of follow-up (range 22-30 
years) in the Swedish randomized controlled mammography trials showed that women 
invited to mammography screenings had a significant 15% relative reduction in breast 
cancer mortality compared to those that were not invited (Nystrom et al., 2016). 
Unfortunately, in women aged 40-48, the mammography did not significantly reduce the 
mortality for breast cancer (Moss et al., 2006). Consequently, young women from age 30, 
at high-risk of developing breast cancer (i.e. with a family history for breast and ovarian 
cancer) are screened with magnetic resonance imaging in combination with mammography. 
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According to the National Institute for Health and Care Excellence, women who have 
close blood relatives with breast cancer (either first-degree female relative - mother, sister, 
daughter - or father or brother) have indeed a higher risk of developing the disease, and 
~20% of these individuals have inherited mutations in high-penetrant genes, such as 
BRCA1, BRCA2, TP53 and PTEN. In this context, testing for mutations in BRCA1 and 
BRCA2 is another important screening strategy to identify women at risk of developing 
breast cancer that should be enrolled in cancer prevention programs and genetic 
counselling (King et al., 2003).  
 
1.5. Management 
Treatment of breast cancer patients varies according to several factors, including tumour 
stage, ER status, other tumour characteristics and menopausal status. 
Surgery alone is the primary treatment for early stage breast cancer and its aim is to 
completely eradicate the primary tumour to reduce the risk of local recurrences. Pathologic 
staging of the tumour and sentinel lymph nodes during resection is necessary to obtain 
prognostic information. There are two main types of surgery for breast cancer: i) breast-
conserving surgery, in which only the tumour mass and the surrounding normal tissue are 
removed; ii) and mastectomy, in which the entire breast is removed to reduce the risk of 
disease relapse (Schuur and DeAndrade, 2015). 
Together with surgery, many patients with more advanced tumours are treated also 
with radiation and chemotherapy. Radiotherapy is well tolerated by most of the patients 
and side effects are usually limited to the treated area, although there is a small risk of 
treatment-induced secondary malignancies (~0.5% in patients affected by breast cancer 
resident in the North and South Thames regions) (Roychoudhuri et al., 2004). There are 
two types of radiation therapy: external beam radiation, in which the radiation is focused 
from a machine outside the body; and brachytherapy (or internal radiation), in which a 
device containing radioactive seeds is placed for a short time into the breast tissue in the 
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tumoral area (Polgar and Major, 2009). 
Pharmacological therapy comprises of chemotherapy and targeted therapy. 
Chemotherapy is used to treat cancer with high risk of relapse or metastatic spread to other 
tissues in the body (adjuvant systemic chemotherapy), to reduce tumour size before 
surgery, and to treat metastatic breast cancer. Although side effects are drug specific, some 
are common to all: e.g., nausea, fatigue, hair loss and increased risk of developing 
infections. 
Chemotherapy includes:  
• Taxanes, commonly used chemotherapeutic agents for the treatment of early stage 
breast cancer that inhibit microtubule polymerization, which leads to apoptosis in a 
subset of the arrested population (Fauzee et al., 2011). 
• Anthracyclines, used in the treatment of early stage breast cancer for decades, 
although concerns regarding anthracycline-associated cardiotoxicity or 
leukemogenic potential remain (EBCTCG, 2005). These agents target 
topoisomerase II (TOP2) by intercalating into DNA, binding to TOP2, disrupting 
its function and inducing the DNA-damage response (Minotti et al., 2004).  
• Tamoxifen, used in the treatment of ER-positive breast cancer. This drug decreases 
the ability of oestrogen to stimulate growth by binding directly to the ER 
(MacGregor and Jordan, 1998). 
• Aromatase inhibitors, used in the treatment of ER-positive breast cancer. These 
drugs inhibit aromatase, the enzyme responsible for converting adrenal androgen 
substrate androstenedione into oestrogen (Altundag and Ibrahim, 2006). 
Therapies that target specific molecular characteristics of cancer cells are called targeted 
therapies. Since these drugs have a precise molecular target in cancer cells, which is 
normally unaltered in normal cells, they are usually less toxic and more effective than 
standard chemotherapy. Some targeted therapies are based on antibodies that work 
similarly to endogenous antibodies produced during the immune response. These types of 
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targeted therapies are also called immune targeted therapies. Among the targeted therapies, 
we find those based on monoclonal antibodies: 
• Bevacizumab that works by inhibiting the vascular endothelial growth factor 
(VEGF), resulting in the block of angiogenesis that cancer cells depend on to grow 
and function (Ellis, 2006). 
• Trastuzumab (Herceptin) and Pertuzumab that both work against HER2-positive 
breast cancers by blocking the ability of the cancer cells to receive growth signals 
via HER2. It binds directly the extracellular domain of the tyrosine kinase receptor 
HER2 (Valabrega et al., 2007). 
• T-DM1 or ado-trastuzumab emtansine is a combination of Trastuzumab and the 
chemotherapy medicine emtansine. T-DM1 was designed to deliver emtansine to 
cancer cells in a targeted way by attaching emtansine to Trastuzumab. Trastuzumab 
then carries emtansine to the HER2-positive cancer cells, inducing mitotic arrest, 
apoptosis, mitotic catastrophe and disruption of intracellular trafficking (Barok et 
al., 2014). 
Targeted therapies also include small molecule inhibitors, such as: 
• Palbociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that works by 
inhibiting cancer cells proliferation (Cadoo et al., 2014). 
• Everolimus, an mTOR (mammalian target of rapamycin) inhibitor whose effect is 
on the mTORC1 protein complex. Everolimus binds to its protein receptor FKBP12, 
which directly interacts with mTORC1 inhibiting its downstream signalling. 
Everolimus has an important effect on cell growth, cell proliferation and cell 
survival. (Houghton, 2010). 
• Lapatinib that works against HER2-positive breast cancers inhibiting tumour cell 
growth. Lapatinib enters the cell and binds directly to the ATP-binding pocket of 
the HER2 intracellular tyrosine kinase domain (Untch and Luck, 2010).  
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2. Breast Cancer Genetics 
In the last years, many efforts have been made towards identifying genes involved in the 
risk of developing, establishment, growth and dissemination of breast cancer. For example, 
genetic tests involving the analysis of the mutational status of BRCA1 and BRCA2 are 
routinely performed in the case of breast cancer familiarity for breast cancer surveillance. 
These genes are defined as high-penetrance breast cancer genes. The BRCA1 and BRCA2 
genes encode for nuclear phosphoproteins that are involved in maintaining genomic 
stability and act as tumour suppressors (Savage et al., 2014; Shahid et al., 2014) About 
40% of inherited breast cancers carry mutations in BRCA1 gene, and tumours with BRCA2 
mutations generally exhibit loss of heterozygosity of the wild-type allele. In addition to 
BRCA genes, other DNA repair genes that interact with BRCA1/2 and/or with BRCA 
pathways can confer an increased risk of developing breast cancer. These genes include: 
ATM (Renwick et al., 2006), CHEK2 (Meijers-Heijboer et al., 2002), BRIP1 (BACH1) 
(Seal et al., 2006), and PALB2 (Rahman et al., 2007). ATM is a cell cycle checkpoint 
kinase that regulates several downstream proteins such as TP53 and BRCA1, and is 
required for the DNA damage response (Bhoumik et al., 2005). CHEK2, a cell cycle 
checkpoint regulator and member of the CDS1 subfamily of serine/threonine protein 
kinases, is able to stabilize p53 protein, controlling cell cycle arrest, and also interacts with 
BRCA1 (Zannini et al., 2014). BRIP1, DNA-dependent ATPase, 5’-3’ DNA helicase and 
member of the RecQ DEAH helicases family, is involved in DNA double-strand break 
repair by interacting with BRCT repeats of BRCA1 (Cantor et al., 2001). Finally, PALB2 
binds to BRCA2 promoting its stabilization in the nucleus and its checkpoint functions 
(Park et al., 2014). 
Despite the identification of these and other genes involved in breast cancer, it is 
clear that the molecular complexity of breast cancers cannot be explained by using only a 
small subset of mutated genes. Indeed, The TCGA, analysing the molecular profiles of 
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hundreds of patients affected by breast cancer, identified novel significantly mutated genes 
(including BX3, RUNX1, CBFB, AFF2, PIK3R1, PTPN22, PTPRD, NF1, SF3B1 and 
CCND3), together with known cancer genes implicated in breast cancer (Cancer Genome 
Atlas, 2012). For this reason, breast cancer should be considered as a molecularly 
heterogeneous disease and more effort should be made to identify novel molecular 
determinants to refine breast cancer diagnosis and to identify cancer druggable targets.  
The molecular heterogeneity of breast cancer can be classified as intertumoral 
heterogeneity, which describes differences among tumours from different patients, and 
intratumoral heterogeneity, which describes differences between cancer cells within the 
same tumour (Russnes et al., 2011). Several hypotheses have been proposed to explain the 
origin and evolution of this molecular heterogeneity and the impact of heterogeneity on 
tumour onset and progression. Here below we briefly explain the different proposed 
theories and their impact on breast tumour aetiology and dissemination.  
 
2.1 Tumour Heterogeneity 
2.1.1. Intertumoral Heterogeneity 
Given the variety of different subtypes in which breast cancer is classified, several 
hypotheses have been made to define and explain this heterogeneity. Two principal models 
have been proposed: 
• Subtype-specific cell of origin, in which each tumour subtype originates from a 
specific type of cell (Figure 4A). 
• Single cell of origin, in which the cell of origin is the same for each subtype and the 
tumour phenotype is determined by acquisition of genetic and epigenetic changes 
(Figure 4B).  
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Figure 4. Inter-tumour Heterogeneity models. A) Subtype-specific cell of origin model: in dark 
red progenitor cell of Basal-like, triple negative tumours; in light blue progenitor of both HER2 
tumours (grey) and Luminal tumours (dark and light blue); B) Single cell of origin (light red) 
model: black, red and blue dots represent tumour type-specific transforming events, that originate 
the different tumour subtypes. Taken from Polyak, 2007. 
 
2.1.2. Intratumoral Heterogeneity 
Intertumoral genetic heterogeneity has been recognized for decades (Fidler, 1978; Perou et 
al., 2000; Sorlie et al., 2001). In contrast, intratumoral heterogeneity was only recently 
discovered when genome-wide microarray gene expression profiling, chromosome copy 
number analysis, and Next-Generation Sequencing (NGS) were employed (Gerlinger et al., 
2012; Navin et al., 2011). These technologies enabled the molecular characterization of 
distinct sub-populations of cancer cells within the bulk tumour population, which 
contributed to the identification of additional cancer genes involved in metastatic spread 
(Nguyen et al., 2016). Moreover, recent studies have shown that different regions of the 
same tumour may have distinct genetic alterations, which indicates the existence of 
different sub-populations confined into geographically distinct sectors of the tumour 
(Gerlinger et al., 2012). With the advent of NGS (Kim et al., 2008) many studies were 
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designed toward a better and deeper understanding of the spectrum of mutations in the 
bulk tumour population and in specific sub-populations of tumour cells (Ding et al., 2010; 
Navin et al., 2011). Furthermore, single cells can be now captured from the entire tumour 
and mutations and copy number variations can be detected in order to separate and 
reconstruct the diversity of sub-populations (Navin et al., 2011).  
To explain intratumoral heterogeneity different models have been proposed: 
• Clonal Evolution Model, in which clonal tumour progression gives rise to the 
genetic heterogeneity, starting either from a single monoclonal sub-population or 
from multiple polyclonal sub-populations (Figure 5A). 
• Cancer Stem Cell Model, in which at a certain time a tumour cell acquires stem cell 
properties and originates the whole population of the tumour. In this model, the 
final population of the tumour can derive either from a single progenitor or multiple 
progenitors (Figure 5B). 
• Mutator Phenotype Model, in which each cell within the tumour has in principle a 
distinct genetic and epigenetic profile (Figure 5C). 
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Figure 5. Model of intratumoral heterogeneity. A) Clonal Evolution Model, in which either one 
(monoclonal) or more (polyclonal) tumour clones gives rise to the final bulk tumour population; B) 
Cancer Stem Cell Model, in which single (red dots) or multiple (red, yellow and black dots) 
progenitors originate the final tumour; C) Mutator Phenotype, in which every cell has a distinct 
genetic and epigenetic profiles; D) Phenotype of tumour cells population according to each model. 
Taken from Russnes et al., 2011. 
 
2.2. Cancer Stem Cells and Breast Cancer Stem Cells 
According to the hematopoietic stem cell (HSC) paradigm, stem cells are slowly dividing 
cells able either to divide asymmetrically, which give rise to one new stem cell and one 
progeny, or to divide symmetrically originating two identical daughter stem cells. HSC 
have also the capability to originate progeny that enter the irreversible process of 
differentiation. Despite this model of stem cell has been applied to all tissues, it is not 
always true and demonstrated for each tissue. For example, in oesophagus, skin, intestinal 
crypts, stomach gland and testis, stem cells are abundant and divide symmetrically with a 
not pre-determined  life span (Clevers, 2015). In addition, it was demonstrated that 
differentiated cells in airway epithelium and in stomach gland tissues are able to revert 
their committed fate to multipontent stem cell fate upon loss of stem cell pools. In contrast, 
in mammary tissue two main models have been proposed to describe the types of stem 
cells: i) the model in which rare multipotent cells with the capability to originate both basal 
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and luminal progenitors are present in breast tissue (Shackleton et al., 2009; Rios et al., 
2014); ii) the unipotent cells model, which encompass the presence of specific stem cells 
for each breast lineage (Van Keymeulen et al., 2011).  
In the 90s, it was postulated that CSCs originate from normal stem cells (Bonnet 
and Dick, 1997), but recent evidence suggests that in many cancers the cancer stem cell 
compartment arises from progenitor cells that acquire the ability to self-renew (Clarke and 
Fuller, 2006; Reya et al., 2001). The first theory is supported by evidence that CSCs share 
features of normal stem cells, such as self-renewal and differentiation capabilities. In 
addition, normal stem cells could acquire mutations and oncogenic transformation during 
their long lifespan (Ginestier et al., 2007; Ponti et al., 2005) transforming them into CSCs 
(Figure 6A). 
On the other hand, in the second scenario, progenitors that undergo epithelial-to-
mesenchymal transition (EMT) were shown to be prone to transformation and to acquire 
characteristics and behaviours of neoplastic stem cells (Mani et al., 2008; Morel et al., 
2008) (Figure 6B). 
 
 
Figure 6. Origin of Breast CSCs. A) Normal mammary stem cell that gives rise to a breast cancer 
stem cell through oncogenic transformation, which then differentiates into the final tumour cell; B) 
Non-stem cell that, via epithelial-to-mesenchymal transition (EMT) and oncogenic transformation, 
originates a cancer cell that acquires stem cell abilities. Solid lines represent experimentally 
demonstrated events; dashed lines represent not yet confirmed events. Taken from Velasco-
Velazquez et al., 2012. 
 
EMT is the process in which epithelial cells lose the tight junctions typical of the 
epithelial phenotype and acquire mesenchymal properties, including fibroblastoid 
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morphology and increased motility, allowing them to migrate (Kalluri and Weinberg, 
2009). EMT was first observed during embryonic development and is essential for normal 
wound healing.  
The ability of mesenchymal cells to spread and self-renew may link EMT to CSCs. 
Indeed, recent evidence suggests that the EMT process may promote the generation of 
cancer cells with the mesenchymal characteristics needed for dissemination (Hollier et al., 
2009). Therefore, the induction of EMT in immortalized human mammary epithelial cells 
results in an increased capacity to form mammospheres and generate cells with a stem cell 
signature (Mani et al., 2008). In addition, EMT was shown to have a role in drug resistance 
and disease recurrence in patients affected by breast cancer (Oliveras-Ferraros et al., 2012; 
Creighton et al., 2009). This involvement is supported by the fact that some circulating 
tumour cells (CTCs) from breast cancer patients possess both epithelial and mesenchymal 
features and that mesenchymal CTCs are enriched during tumour progression (Yu et al., 
2013). 
 
2.2.1. Breast Cancer Stem Cells Markers 
Different markers have been identified to isolate breast CSCs. The vast majority are 
composed of surface markers, such as the CD44 and CD24 proteins. In breast cancer, Al-
Hajj et al. (Al-Hajj et al., 2003) demonstrated that a subpopulation of the initial tumour, 
composed of ESA+/CD44+/CD24−/low, were the only cells able to generate a tumour when 
transplanted in NOD/SCID mice. Subsequently, several studies have confirmed their 
results (Liang et al., 2013; Pece et al., 2010; Ponti et al., 2005). In addition, the 
intracellular enzyme ALDH1 (aldehyde dehydrogenase 1) was also used to enrich breast 
CSCs. Indeed, ALDH1+ cells were able to give rise to tumours in NOD/SCID mice 
(Ginestier et al., 2007). 
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Notably, both populations of cells, ESA+/CD44+/CD24−/low and ALDH1+, have the ability 
to form mammospheres, spherical clonal colonies of cells grown in non-adherent 
conditions and enriched in CSCs (Dontu et al., 2003). 
2.2.2. Clinical Implications of Cancer Stem Cells 
Since metastatic breast cancer is one of the major causes of death from breast tumours, it is 
important to understand which mechanisms are responsible for metastasis. To determine 
the role of CSCs in the metastatic process, Balic and colleagues (Balic et al., 2006) 
examined the expression of cancer stem cell markers in metastatic lesions of bone marrow 
in patients with breast carcinoma. They found an high CD44+/CD24−/low expressing cells in 
disseminating tumour cells of bone marrow of patients affected by breast cancer indicating 
an enrichment of the cancer stem cell compartment.  
While the presence of micrometastasis is associated with poor prognosis (Braun et 
al., 2005), ~50% of patients with such metastasis do not develop macrometastasis within a 
10-year follow up period.  
Since CSCs have both the characteristics to remain quiescent for a long time and to 
give rise to an offspring of proliferating cancer cells, in the case of a suboptimal surgery or 
chemotherapy (which does not eliminate all CSCs), the risk of the disease evolving into a 
metastatic cancer is considerable. Therefore, it is important to understand the molecular 
features of CSCs in order to develop specific targeted therapies to eradicate CSCs 
themselves, and inhibit metastasis onset and disease progression. 
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3. Cancer Genomics 
During its lifetime, a cell acquires set of differences from its parent cell and this happens 
also to cancer cells. Such differences encompass several DNA sequence changes: 
• Somatic mutations, single nucleotide variations that affect somatic cells. 
• Insertions or deletions of small or large portions of DNA. 
• Rearrangements, switching of DNA fragments from one position in the genome to 
another. 
• Copy number variations that comprise loss of copy number (from 2 to 1 or zero) 
and gain of copy number (more than 2 copies). 
In addition, a cancer cell may acquire further epigenetic alterations (chromatin structure, 
methylation and gene-expression alterations) that can be inherited by daughter cells and 
augment malignancy (GrØnbÆk et al., 2007; Loden et al., 2002). 
Somatic mutations can be classified, according to their consequences, as: i) “driver” 
mutations that confer a growth advantage and are positively selected during the evolution 
of the cancer; ii) “passenger” mutations that are not selected and which do not confer any 
growth advantage, thus, not directly involved in cancer development. However, these 
mutations might have a role in promoting the establishment of “driver” mutations (Pon and 
Marra, 2015). Driver mutations are present within a subset of genes known as cancer genes. 
Most of these cancer genes were discovered and studied during the last decades. In 2004, 
at least 350 (1.6%) of the 22,000 protein-coding genes in the human genome were shown 
to harbour recurrent somatic mutations in cancer with strong evidence that these contribute 
to cancer development (Cancer Gene Census) (Futreal et al., 2004). Nowadays, the Cancer 
Gene Census comprises around 570 cancer genes with somatic mutations causally implied 
in cancer. 
The identification of cancer genes led to the development of genetic tests, which 
aim to identify whether a particular gene or set of genes is mutated in a tumour sample and 
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to guide treatment decision-making. In addition, specific therapies have been developed, 
based on mutated genes, in order to target mutated cancer cells specifically, without 
affecting normal cells. 
Until recently, most genetic tests for cancer focused on testing for either 
individually inherited mutations or exons of disease-specific cancer genes. However, as 
more efficient and cheaper DNA sequencing technologies have become available, 
sequencing of an individual’s entire genome or the DNA of an individual’s tumour is 
becoming more common. In this direction, consortia of clinical laboratories have been 
established. 
Moreover, as reported by Dr. Gad Getz, Director of Cancer Genome Computational 
Analysis at the Broad Institute of the Massachusetts Institute of Technology (MIT), most 
genes are mutated in a small percentage of patients (at intermediate frequencies, 2 to 20% 
of patients, or lower) (http://cancergenome.nih.gov/). While frequently mutated genes 
seem to be easier to be identified and studied, infrequently mutated genes have long eluded 
researchers. Therefore, several strategies have been recently proposed to prioritize cancer-
relevant genes that are mutated at low frequencies. Most of these strategies are based on 
pathway-oriented analyses of mutated genes and their mutual exclusivity that could 
indicate their function within a common molecular mechanism (Dees et al., 2012; 
Leiserson et al., 2015; Vaske et al., 2010). 
 
3.1. Genomics in Medicine (Consortia) 
Many efforts are being made to identify a more exhaustive map of cancer genes. 
Such analyses are made difficult by the high genetic heterogeneity of cancer, which 
complicates the identification of cancer driver genes that frequently appear to be mutated 
only in a low percentage of patients (i.e. similarly to passenger gene mutations). For this 
reason, international collaborative studies have been set up to try to overcome such 
limitations through the launch of high-throughput genetic screening (based on NGS) of 
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hundreds of tumour samples, from various cohort of patients with different types of cancer. 
Here below is a brief summary of the most important studies: 
 
3.1.1. The Cancer Genome Atlas (TCGA) 
TCGA is a collaboration between the National Cancer Institute and National 
Human Genome Research Institute (http://cancergenome.nih.gov/). The aim of this 
consortium is to generate comprehensive, multi-dimensional maps of the key genomic 
changes in major types and subtypes of cancer. It comprises 33 cancer types regarding 
most commonly affected tissues, including breast, lung, blood cells, brain, kidney, skin and 
uterus, with a total of 11,353 analysed cases (https://gdc-portal.nci.nih.gov/). Patients are 
asked to donate a portion of tumour tissue together with normal tissue, typically blood. 
These tumour and normal samples are subjected to different kinds of analysis: 
• DNA analyses, including whole-exome sequencing, methylation via bisulfite 
sequencing and array-based and copy number identification. 
• RNA analyses, including total RNA sequencing, gene expression analyses through 
sequencing and array-based, and miRNA sequencing. 
• Microsatellite instability (Velasco-Velazquez et al., 2012). 
• Protein expression. 
 
3.1.2. International Cancer Genome Consortium (ICGC) 
The ICGC (http://icgc.org/) was created to launch and coordinate a large number of 
research projects with the common aim of elucidating comprehensively the genomic 
changes present in many forms of cancers. The primary goal of the ICGC is to generate 
complete catalogues of genomic abnormalities (somatic mutations, abnormal expression of 
genes, epigenetic modifications) in tumours from 50 different cancer types and/or subtypes 
that are of clinical importance. Differently from the TCGA, the ICGC gathers together 
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projects coming from countries worldwide. Almost every continent is represented by at 
least one research group within the ICGC. It is also made of two different committees, 
composed of members grouped by specific aims.  
 
Such collaborative studies allowed us to create high-resolution molecular portraits 
of different cancer types (Alexandrov et al., 2013; Cancer Genome Atlas, 2012; Cancer 
Genome Atlas Research, 2014; Cancer Genome Atlas Research et al., 2016) and to identify 
novel cancer genes and cancer pathways with obvious positive implications in the 
management of cancer patients. 
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4. Next-Generation Sequencing 
4.1. Brief History of Next-Generation Sequencing 
In 2005, the first NGS technology was released, Roche 454, and posed the basis of a new 
sequencing era. In contrast to the canonical Sanger sequencing method NGS has three 
major improvements: 
• It is based on library preparations instead of bacterial cloning. 
• Thousands to millions of sequencing reactions are performed in parallel. 
• The output is directly detected without the electrophoresis step. 
In 2006, Solexa/Illumina commercialized its own sequencing technology 
(http://www.illumina.com/), which was followed by Applied Biosystems’s SOLiD 
platform (Life Technologies) in 2007 
(http://www.thermofisher.com/it/en/home/brands/applied-biosystems.html) and by Ion 
Torrent’s Personal Genome Machine (Life Technologies) in 2010 
(https://www.thermofisher.com/it/en/home/brands/ion-torrent.html). 
The four technologies listed above have different sequencing chemistries. Roche 
454 is based on released pyrophosphate that emits light (pyrosequencing). Illumina is 
based on sequencing-by-synthesis chemistry, in which each DNA fragment is copied 
through bridge amplification and then sequenced using fluorescent-tagged nucleotides. The 
SOLiD platform is based on sequencing by ligation, during which octamers are ligated 
together and when the ligation takes place a fluorophore is released and the light detected. 
The Personal Genome Machine sequencer is similar to Roche 454, but instead of 
pyrophosphate being released, it releases a proton during nucleotide incorporation, which 
is detected by ion sensors. 
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4.2. Next-Generation Sequencing Platforms 
Nowadays, there are three major platforms for sequencing projects that are present in 
research institutes: Applied Biosystems SOLiD, Illumina HiSeq2000 and Ion Torrent Ion 
Proton. 
4.2.1 Illumina Sequencing 
Illumina sequencing technology is based on sequencing-by-synthesis chemistry. Each 
DNA strand is copied and when a single nucleotide is incorporated in the new filament, it 
emits a fluorescent signal that is detected. 
Peculiar to Illumina sequencing is the amplification of each DNA filament through 
the so-called bridge amplification. In this step, each DNA fragment that is attached to the 
solid surface of the flowcell (Figure 7A), falls over and the adaptor at the end of the 
fragment then attaches to a probe on the flowcell itself (Figure 7B). The bridge-like 
structures form the templates for amplification to generate clusters comprising clonally 
amplified copies of the DNA fragment on the surface of the flowcell (Figure 7C).  
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Figure 7. Illumina Sequencing Workflow. A) DNA fragments (blue, green and red bars) are 
ligated with adapters (short black and light grey bars) and then attached to the flowcell surface 
(grey parallelepiped); B) Each fragment is bridge-amplified, until the generation of clusters; C) 
After cluster formation reaches a plateau the sequencing-by-synthesis starts (complementary bases 
are incorporated in the new DNA filament, emitting a fluorescence, which is detected by a light-
detector). Adapted from http://www.intechopen.com/books/next-generation-sequencing-advances-
applications-and-challenges/next-generation-sequencing-in-aquatic-models. 
 
Illumina sequencing-by-synthesis is mediated by polymerase enzymes that use four 
different reversible nucleotides labelled by four different fluorescent colours. The 
nucleotides are reversible terminators: one terminator nucleotide is incorporated into the 
synthesis of the complementary strand and then washing steps are applied to remove the 
extra nucleotides and reagents. The imaging of the fluorescence signals is followed across 
the whole flowcell, and, after imaging, the 3′ blocking group of the reversible terminator 
nucleotide is cleaved. These steps are then repeated until the synthesis of the 
complementary strand is complete. 
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4.2.2. Ion Torrent Sequencing 
The Ion Torrent sequencing technology is based on the detection of H+ ions, that are 
naturally released when a nucleotide is incorporated into a DNA strand by DNA 
polymerase.  
DNA is fragmented and each fragment is attached to its own bead and then it is copied all 
over the bead. Since every fragment is attached to one bead, at the end millions of beads 
are obtained. Beads are then placed into the wells that compose the chip. At each cycle of 
polymerization, a solution with only one nucleotide type is added to the wells. If the 
nucleotide is incorporated into the new DNA strand, H+ is released and the pH changes. 
The variation in pH is converted into a voltage and a base is called (Figure 8). 
Subsequently, the solution is washed and another nucleotide is added to the wells. This 
addition, detection and washing workflow is repeated until the completion of synthesis of 
the complementary DNA strand, in every single well of the chip. 
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Figure 8. Principles of the Ion Torrent Sequencing Reaction. The Ion Torrent Sequencing 
reaction is based on a sequencing-by-synthesis reaction in which the DNA template being 
sequenced is immobilized and a complementary DNA strand is synthesized by the sequential 
addition of single nucleotides. In the synthesis reaction, the incorporation of a nucleotide to a 
complementary DNA strand is converted into a voltage increase by measuring the release of a 
hydrogen (H+) ion. Top panel, cartoon depicting the synthesis of a complementary DNA strand 
during an Ion Torrent sequencing reaction. In red: template strand, yellow: complementary strand; 
green: DNA polymerase. The release of H+ ion during the incorporation of a nucleotide to the 
complementary strand is also shown. Bottom panel, depicted the detection of voltage increase 
induced after the pH change resulting from the release of an H+ ion is shown. Adapted from 
www.thermofisher.com. 
 
If a nucleotide is not incorporated into the complementary DNA strand, then no H+ ion is 
released, no voltage change is recorded and no base is called. If two or more bases of the 
same type are incorporated, two or more H+ ions are released and the voltage changes 
proportionally (Figure 9). 
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Figure 9. Ion Torrent Sequencing Reaction in Critical Regions. In top panel cartoon depicting 
the synthesis of a complementary DNA strand during an Ion Torrent sequencing reaction when two 
bases of the same type are incorporated. In red: template strand, yellow: complementary strand; 
green: DNA polymerase. The release of H+ ions during the incorporation of two nucleotides to the 
complementary strand is also shown. Bottom panel, depicted the detection of voltage increase 
induced after the pH change resulting from the release of two H+ ions is shown. Adapted from 
www.thermofisher.com. 
 
4.3. Advantages and Disadvantages 
NGS technology has many advantages. First, NGS permits the sequencing of the entire 
genome of a cell in a shorter timeframe compared with Sanger sequencing, thus enabling 
the use of NGS platforms in clinics and even in small laboratories. Second, for some 
applications, it does not require a priori knowledge of the genome, since data are de novo 
assembled. Third, it generates billions of data in a very short time, increasing our discovery 
potential. 
Another advantage of NGS is the high versatility of each platform: with only one 
instrument, it is possible to generate data for different applications, spanning from the 
basic Whole Genome (WGS) and Whole Exome sequencing (WES), to RNA sequencing 
(both mRNA and miRNA), to epigenomic applications (e.g. methylation and DNA-protein 
interactions). NGS also requires less starting material, both for DNA and RNA sequencing, 
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and permits the sequencing of multiple samples in parallel, with the use of specific 
barcodes ligated to DNA/RNA from individual samples. 
Although NGS has improved our ability in terms of DNA and RNA sequencing, 
some concerns have been raised. Firstly, sequencing chemistry does not permit the 
sequencing of very long fragments of DNA/RNA. Second, given the loss in precision of 
polymerase used for the sequencing itself, the precision and fidelity of the last bases of the 
reads is lower compared with the other bases, thus, reducing, although not significantly, 
the throughput. Another problem is the cost of the instrumentation, that is lower compared 
to the first sequencers, but still remains high (80,000-600,000 euros) and not always 
affordable. Last but not least, the problem of data storage, since the amount of data 
produced in a single run of sequencing is huge and typically a laboratory performs several 
runs. In this scenario, every research centre has invested either in server storage with high 
costs or in cloud storage which is less costly but more vulnerable. 
 
4.4. Next-Generation Sequencing in Cancer Research 
The rapid developments and improvements of high-throughput sequencing technologies 
have not only revolutionized our approach to -omics studies, but they have also changed 
the genomic medicine context. Besides classical and canonical one/few-gene tests, NGS 
platforms have appeared in clinical laboratories. This has determined an increase in their 
translational use. 
An important aspect of the use of NGS is the unbiased view of the alterations in the 
genome. Hence, in cases where there is no prior knowledge of genetic aberrations 
underlying the cancer phenotype, the approach to sequence either the entire genome or 
exomes results in a deeper and more accurate identification of modifications that drove the 
onset and progression of cancer.  
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4.4.1. Targeted Resequencing 
As genomic instabilities that lead to cancerous growth can be due to point mutations in 
coding regions, exome sequencing has become a natural choice for detecting them. 
Because mutations in coding regions generally lead to changes in protein structure, exome 
sequencing is also relevant for developing targeted drug therapies and assessing resistances 
that may occur during treatment. Targeted resequencing has now entered in the clinic and 
offers a clear advantage by using small quantities of nucleic acids to screen multiple genes 
at a time. Although exome sequencing is not yet the main approach in the clinic, a variety 
of panels of genes are becoming more frequently applied to identify mutations in known 
cancer-related genes. Indeed, several sequencing companies are producing panels of genes, 
specific for each cancer type, together with customizable panels, in order to help clinical 
laboratories not only in their diagnostic routine, but also in clinical research. 
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Rationale 
Breast cancer is a heterogeneous disease characterized by high inter- and intra-tumoral 
molecular heterogeneity. This makes diagnosis, the prediction of prognosis and the 
standardization of treatments more difficult, and ultimately has a negative impact on breast 
cancer therapy. Thus, deciphering this molecular heterogeneity should lead to 
improvements in the care of breast cancer patients.  
Recent genome-wide profiling studies have analysed in-depth the genomic profiles 
of several breast tumours using NGS. These studies indicate that breast tumours can be 
either: i) monogenomic, comprised of a single clonal cell population; ii) or polygenomic, 
composed of several related clonal subpopulations (Navin et al., 2011). In the first case, 
the metastatic spread of the disease appears to be driven by cells resulting from a single 
clonal expansion and which have undergone little further evolution, while, in the second 
case, metastasis is driven by a minor subpopulation of cells that has acquired ‘metastatic’ 
cancer-driving mutations (Ding et al., 2010; Navin et al., 2011). In addition to this 
temporal dimension, in renal carcinoma, Gerlinger and colleagues (Gerlinger et al., 2012) 
found that intratumoral heterogeneity can also have a spatial dimension. Indeed, NGS of 
different regions within the same primary tumour revealed not only shared but also private 
mutations. 
Different models have been proposed to explain the origin and evolution of breast 
intratumoral heterogeneity: i) the Clonal Evolution Model; ii) the Cancer Stem Cell Model; 
and iii) the Mutator Phenotype Model (Russnes et al., 2011).  
In the Clonal Evolution Model, genetic and epigenetic changes occur over time in 
individual cancer cells. If such changes confer a selective advantage they will allow 
individual cancer cell clones to out-compete other clones and give rise to the final tumour 
mass. Similarly to the Clonal Evolution Model, in the Cancer Stem Cell Model, the cells 
that undergo advantageous genetic and epigenetic changes may also acquire the ability of 
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self-renewal, thus transforming these cells into CSCs. The last model is the most dramatic 
one: the Mutator Phenotype Model, which describes a situation whereby each single cell 
has a distinct genetic and epigenetic profile. In this scenario, it is extremely hard to identify 
cancer-driving mutations that sustain tumour growth and progression. 
Here, we hypothesized that mutational events that drive the onset and progression 
of breast tumours lie within the cancer stem cell compartment. Our hypothesis is supported 
by several experimental observations that demonstrate the ability of CSCs to recapitulate 
fully malignant breast tumours (Fillmore and Kuperwasser, 2008; Ponti et al., 2005). In 
particular, tumours with low cancer stem cell content are less able to give rise to PDXs in 
limiting dilution conditions, and such tumours are frequently low-grade (G1) tumours 
associated with a less aggressive behaviour compared with tumours with a higher stem cell 
content (Pece et al., 2010). In addition, it has been demonstrated that the molecular profile 
of normal breast stem cells can distinguish molecularly breast cancer patients with an 
adverse prognosis (Ben-Porath et al., 2008; Pece et al., 2010).  
To test this hypothesis, we used NGS, specifically, WES, to perform a comparison 
of the genetic profiles of a primary breast tumour with its matched mammospheres 
(enriched in CSCs) and PDX. Our goal was to identify mutations enriched in CSCs that 
might be relevant for breast cancer progression. We setup a NGS protocol to identify rare 
mutations in the primary tumour that are present in the cancer stem cell compartment, 
using low amounts of input DNA. Of note, the low frequency mutations in putative novel 
cancer oncogenes can be diluted within the NGS technical noise and therefore missed. 
Hence, we proposed that our approach, based on the direct analysis of mammospheres and 
PDXs matched with primary breast tumours, could be an effective tool for the 
identification of cancer-relevant, CSC-specific low frequency mutations, which should be 
enriched and therefore detectable at a higher frequency in the short proliferative history of 
mammospheres and PDXs. This will enable us, in the long run, to identify new potential 
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druggable targets for the development of targeted therapies, which is particularly relevant 
to cases where canonical and known cancer genes are unaltered. 
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Material and Methods 
1. Sample Collection 
Primary tumour, embedded in Optimal Cutting Temperature compound, and blood were 
collected from the IEO Biobank from a patient, aged 55, with infiltrating duct breast 
carcinoma. The tumour is a Luminal B (HER2-negative, ER-positive, PR-positive assessed 
by immunohistochemistry) and moderately differentiated (grade II) breast tumour as 
determined by the Bloom-Richardson score. 
 
2. Patient-Derived Xenograft (PDX) and Mammospheres Preparation 
PDX and mammospheres were established starting from the same primary tumour. 
Mammospheres were generated also from PDX sample (PDX-mammospheres). 
Mammospheres, both human- and mouse-derived, were obtained and cultured as 
previously described in (Pece et al., 2010). Briefly, epithelial cells from the primary 
tumour were allowed to adhere for 24 hours in complete SC medium (Dontu et al., 2003). 
Cells were trypsinized, filtered through a 100 mm cell strainer and then through a 40 mm 
cell strainer, resuspendend in PBS and plated in suspension (Dontu et al., 2003). After 7–
10 days, mammospheres were harvested and dissociated enzymatically.  
For the xenotransplant of human breast cancer cells, we proceeded as in (Pece et 
al., 2010). Briefly, tumour biopsy material was dissociated mechanically and 
enzymatically and resuspended cells were then injected directly into cleared mammary fat 
pads of a NOD/SCID mouse. The mouse injected with cancer cells was euthanized when 
the tumour outgrowth reached approximately 1 cm in the largest diameter, to avoid tumour 
necrosis and in compliance with regulations for use of vertebrate animal in research. 
Experiments were performed by Dr Daniela Tosoni in Molecular Medicine for Care 
Program laboratory at European Institute of Oncology, Milan.  
	 46	
3. Sample Processing 
Genomic DNA (gDNA) for NGS experiments was extracted from the primary tumour 
sample, the PDX and mammospheres generated from both the primary tumour and the 
PDX using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s 
instructions. gDNA for the Whole Genome Amplification (WGA) test was extracted from 
additional unrelated normal breast tissue, breast cancer primary tumour and primary 
tumour-derived mammosphere samples with QIAamp DNA Mini Kit (Qiagen) according 
to the manufacturer’s instructions. DNA was extracted from blood using the QIAamp 
Blood Midi Kit (Qiagen) according to the manufacturer’s instructions.  
Since we were dealing with mammosphere samples that are composed of very few 
cells, we tested the smallest amount of gDNA we could use for the genomic amplification 
step. To do so, 5-10 ng of gDNA of the additional unrelated normal breast tissue, breast 
cancer primary tumour and primary tumour-derived mammosphere samples were subjected 
to WGA (Cadwell and Joyce, 1992; Hasmats et al., 2014) with Repli-G Mini Kit (Qiagen).  
Having established that 10 ng was the optimum amount of gDNA to obtain a 
sufficient quantity of DNA for a WES experiment, we subjected 10 ng of gDNA from the 
primary tumour, blood, primary tumour-derived mammospheres, PDX and PDX-derived 
mammospheres samples to WGA, using Repli-G Mini Kit (Qiagen). Experiments were 
performed by Dr Francesca De Santis and Dr Stefania Pirroni in Molecular Medicine for 
Care Program laboratory at European Institute of Oncology, Milan. 
 
4. Whole Exome Sequencing 
To test whether WGA introduced artefacts in the NGS analysis, we performed Illumina 
WES on both gDNA and WGA-DNA obtained from the same tumoral sample test. Three 
µg of both gDNA and WGA-DNA were used to test for sequencing reproducibility and 
thereby establish whether there was any possible Whole-Genome Amplification bias.  
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Based on results from the comparison of gDNA and WGA-DNA, we decided to 
use 3 µg of WGA-DNA obtained from the primary tumour, primary tumour-derived 
mammospheres, PDX and PDX-derived mammospheres for Illumina WES. 
Libraries were constructed using ligation of Illumina adaptors to sheared WGA- 
and gDNA. Hybridizations were performed using Agilent SureSelect All Exome v4.0 kit. 
Paired-end, 100 bp WES (Balic et al., 2006) was performed using HiSeq2000 (Illumina). 
For the Ion Torrent sequencing, 100 ng of the same WGA-DNA samples subjected 
to Illumina sequencing was used as starting material in the AmpliSeq Exome amplification 
step following manufacturer’s protocol (Thermo Fisher Scientific). The final sequencing 
libraries were quantified using the Bioanalyzer 2100 instrument with DNA HS kit (Agilent 
Technologies) and Qubit with dsDNA HS kit (Thermo Fisher Scientific). All libraries were 
diluted to 100pM and then pooled to perform the chip preparation on the Ion Chef 
instrument (Thermo Fisher Scientific) according to manufacturer’s protocols. For our 
samples, we used a total of 6 chips, in order to obtain a sufficient amount of reads to call 
variants. Experiments were performed by Cogentech sequencing facility at IFOM-IEO 
Campus, Milan. 
 
5. Bioinformatic Pipeline 
5.1. Alignment and BAM file generation 
5.1.1 Illumina 
The quality of reads was assessed using FastQC v0.10.1 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Mouse reads from mouse-
derived samples (PDX and PDX-derived mammospheres) were identified and removed 
using Xenome software (Conway et al., 2012).  
For each sample, reads were aligned to the NCBI build 37 (hg19) human reference 
genome sequence using BWA v0.6.2 r126 (Li and Durbin, 2009 We first created .sai files 
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using the bwa aln command. Then, we generated .sam files using the bwa sampe 
command. We sorted .sam files using Picard (http://picard.sourceforge.net). BAM files 
were generated using SAMtools v0.1.18 r982 (Li et al., 2009). Duplicates were marked 
and removed with Picard (http://picard.sourceforge.net). 
5.1.2. Ion Torrent 
Sequence alignment was performed for all samples using the Ion Torrent Suite software 
version 5.0.4. The alignment was performed using the NCBI build 37 (hg19) as the human 
reference genome sequence. 
 
5.2. Xenome Software Test and Evaluation 
We downloaded the Xenome software from http://www.nicta.com.au/bioinformatics and 
tested it using both human and mouse Illumina reads. We downloaded paired-end 100 bp 
mouse reads from the Sequence Read Archive (SRA) (code DRX014750 and DRX014751, 
forward and reverse reads respectively). We used our primary tumour sample reads as pure 
human reads. To evaluate the performance of the Xenome software in identifying mouse 
reads within PDX-derived samples, we performed calibration tests as follows: 
1. We randomly selected human and mouse reads. 
2. We pooled mouse and human reads in order to have different percentage of mouse 
contamination within the human sample (0-50%, step 5%). 
3. We applied the Xenome software to each pool. 
4. We evaluated the performance of Xenome software. 
Having verified the ability of the Xenome software to identify mouse reads, we applied the 
software to our experimental samples and calculated mouse contamination in our PDX-
derived samples. We removed mouse reads from our samples and retained only those reads 
flagged as human or both mouse and human. 
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For Ion Torrent reads, we downloaded from SRA reads derived from a human 
tumour sample (code SRR1531565) and a PDX sample (code SRR1534102) to evaluate 
the performance of Xenome software. We then applied the Xenome software to our Ion 
Torrent PDX-derived samples. 
 
5.3. Mutation Detection and Annotation 
5.3.1. Illumina 
To identify somatic single nucleotide variants (SNVs) and somatic insertion/deletions 
(indels) that were present in the primary tumour, primary tumour-derived mammospheres, 
PDX and PDX-derived mammospheres samples and that were responsible for tumour 
onset and progression, we used VarScan2 software (Koboldt et al., 2012). SNVs and indels 
were annotated with Annovar (Wang et al., 2010).  
To determine not only high frequency, but also rare variants, we used different 
frequency thresholds varying the min-var-freq parameter of VarScan2. We set thresholds 
at 0.01, 0.05, 0.1, 0.15 and 0.20. We are aware that at a frequency of 1 to 5%, called 
variants might be sequencing errors. Therefore, putative somatic mutations were manually 
reviewed using the Integrative Genomic Viewer (IGV) (Robinson et al., 2011; 
Thorvaldsdottir et al., 2013). All plots were generated using the statistical software R (R 
Core Team (2012), R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria). 
5.3.2. Ion Torrent 
Variant calling and variant annotation were performed on the Ion Reporter website after 
uploading BAM files. Somatic variants were called using the AmpliSeq Exome tumour-
normal pair workflow version 5.0 with default parameters. Annotation was performed 
using the Annotate variants single sample workflow version 5.0. Putative somatic 
mutations were manually reviewed using IGV (Robinson et al., 2011; Thorvaldsdottir et al., 
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2013). All plots were generated using the statistical software R (R Core Team (2012), R: A 
language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria).	
 
5.4. Analysis of Mutated Genes 
We checked whether the mutated genes identified in this study are present in published 
databases and, when present, if the mutated base is the same or not as that detected by us. 
We searched for our mutated genes in cBioPortal (Cerami et al., 2012; Gao et al., 2013) 
breast cancer studies: we selected all studies included into the Breast Invasive Carcinoma 
category and we searched for Only Mutation type of data. We downloaded all the 
mutations associated with each gene in our list of mutated genes and compared them to the 
mutations identified in our study. We also downloaded Mutation Data (Genome Screens) 
and Mutation Data version 77 from the COSMIC database (Forbes et al., 2015). 
Furthermore, we determined whether the mutations identified in our study are 
present in specific protein domains and whether the amino acid changes are possibly 
damaging or not. To estimate the damaging potential of a nucleotide substitution, we used 
freely available web tools that are routinely applied by researchers. We used PROVEAN 
(Protein Variation Effect Analyzer) and SIFT (Choi et al., 2012; Doerks et al., 2002; 
Kumar et al., 2009) from J. Creig Venter Institute; FATHMM (Functional Analysis 
through Hidden Markov Models) MKL algorithm (Shihab et al., 2015); PolyPhen-2 
(Polymorphism Phenotyping v2) single and batch query (Adzhubei et al., 2013; Adzhubei 
et al., 2010); Mutation Assessor (Reva et al., 2011); and CADD (Combined Annotation 
Dependent Depletion) web application (Kircher et al., 2014). 
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Results 
1. Optimization of Whole Exome Sequencing Protocol 
To perform WES on our matched primary tumour, PDX and mammosphere samples, it 
was first necessary to optimize the procedure. In particular, since we were attempting to 
perform WES on gDNA derived from mammosphere cultures, which typically contain 
very few cells after 10 days of growth (~3000 cells/patient sample), we introduced a WGA 
step and determined whether this step introduced artefacts in the mutational profiles. We 
also introduced filtering steps to remove potentially contaminating DNA from the mouse 
host in the PDX samples or from other sources (e.g. unrelated individuals). The following 
sections describe in detail these optimisation steps. 
 
1.1. Validation of the Whole Genome Amplification Step  
A critical aspect of our study was the ability to perform WES (Balic et al., 2006) starting 
from limited amounts of gDNA, such as the gDNA extracted from mammosphere cultures; 
each mammosphere is composed of ~300 cells. Therefore, we performed several 
experiments to set up the DNA amplification protocol (WGA) necessary to run WES when 
starting from small quantities of DNA (5-10 ng). We used a gDNA sample present in the 
reaction kit (QIAGEN REPLI-g Mini Kit) as a positive control, water as negative control, 
gDNA extracted from a fresh frozen normal breast tissue sample as a healthy sample, 
gDNA from a fresh frozen primary tumour-derived mammosphere sample, and gDNA 
from a frozen breast primary tumour sample. By applying the WGA technique, we were 
able to obtain a sufficient amount of DNA to perform deep sequencing (~3 µg). In 
particular, starting from 5-10 ng of gDNA from the different frozen samples, we obtained 
> 3 µg of DNA, which is sufficient for WES (Figure 10). 
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Figure 10. Optimization of the WGA protocol. Determination of yield of amplified DNA after 
WGA using different amounts of starting DNA. WGA was performed on 5 and 10 ng of gDNA 
obtained from different samples, including: C+, the positive control, gDNA sample present in the 
reaction kit (QIAGEN REPLI-g Mini Kit); C-, the negative control (water); Normal, gDNA 
extracted from a fresh frozen normal breast sample; Spheres, gDNA from a fresh frozen primary 
tumour-derived mammosphere sample; Tumour, gDNA from a frozen breast primary tumour 
sample. Red dashed line represents the minimum amount of DNA required for an Illumina Whole 
Exome Sequencing experiment (3 µg). 
 
To establish whether the amplification step introduced a bias, or not, in the final 
WES profile, we sequenced both a non-amplified gDNA sample and a WGA-amplified 
DNA sample (WGA-DNA) derived from the same tumoral sample. We compared the two 
mutational profiles and observed a substantial agreement between the two profiles, both in 
terms of read alignment (>90% of aligned reads, 79% of these were “on-target reads” with 
a median depth of coverage of ~120X) (Figure 11) and called variants, with ~80% of 
variants in common (Figure 12). Our results are consistent with results of a recently 
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published paper (Hasmats et al., 2014), which showed that 89% of the variations found by 
WGA-DNA were shared with gDNA. Thus, we concluded that the WGA step did not 
introduce artefacts in WES experiment, enabling us to apply this protocol to our 
experimental samples. 
 
 
Figure 11. The effect of WGA on alignment statistics. Illumina reads of a tumoral test sample 
were obtained by WES using genomic DNA (gDNA) or whole-genome amplified DNA (WGA-
DNA) as starting material. Aligned reads were calculated starting from raw reads of each sample, 
while uniquely aligned reads, on target reads and coverage >=20X were calculated from aligned 
reads. Coloured bars indicate different samples, salmon: gDNA; turquoise: WGA-DNA. 
 
 
 
 
Aligned Reads Uniquely Aligned Reads On Target Reads Coverage >=20X
93% 93% 96% 96%
79% 79%
99% 97%
0
25
50
75
100
gD
NA
W
GA
-D
NA
gD
NA
W
GA
-D
NA
gD
NA
W
GA
-D
NA
gD
NA
W
GA
-D
NA
Sample
V
al
ue
 (%
)
54	
Figure 12. The effect of WGA on variant calling. Mutational profiles of a tumoral test sample 
were obtained by WES using genomic DNA (gDNA) or whole-genome amplified DNA (WGA-
DNA) as starting material. Called variants were obtained by applying the VarScan2 software with 
default parameters. Although more variants were identified in gDNA compared to WGA-DNA, 
more than 80% of them are shared between the two experimental conditions. In brackets the total 
number of variants present in each sample. 
1.2. Whole Exome Sequencing of Matched Primary Tumour, PDX and 
Mammosphere Samples 
Having established that the WGA step did not introduce any substantial bias in the 
identification of genomic variants, we performed the WGA-WES (Whole-Genome 
Amplification followed by Whole Exome Sequencing) analysis of the first primary 
tumour-mammosphere-PDX matched sample from a breast cancer patient, together with a 
blood sample from the same patient as healthy control. We selected a grade 2, Luminal 
B/HER2-negative breast cancer as it was moderately aggressive and without known cancer 
driver events. We have also sequenced the PDX-derived mammospheres to compare their 
mutational profile with that of primary tumour-derived mammospheres. This latter 
comparison might allow us to identify specific clones in the cancer stem cell compartment 
that gave rise to the PDX. 
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Mammosphere samples were cultured for 10 days in suspension, then were 
harvested and dissociated enzymatically. The PDX sample was generated starting from 
dissociated cells from the primary tumour that were injected directly into the mammary fat 
pad of a NOD/SCID mouse. 
Using the WGA step, we obtained on average 4 µg of WGA-DNA (range 3 – 5.5 
µg), a sufficient amount of DNA for WES experiments. After amplification, we subjected 
our WGA-DNA to WES, obtaining an adequate number (>50 million reads) of aligned and 
on target reads (aligned reads = 80 – 140 million reads, on target reads = 65 – 110 million 
reads). Therefore, we were able to call variants, both somatic and germline, identifying a 
comparable number of mutations among all analysed samples (~10,000 mutations per 
sample). 
1.3. Validation of the Xenome Filtering Step to Remove Contaminating Mouse DNA 
An important aspect when dealing with PDX-derived samples is the potential 
contamination of mouse DNA because it is not always possible to eliminate all the mouse-
contaminant cells before sequencing. To control for this potential contamination, we added 
an additional filtering step to our analysis pipeline that uses the Xenome software (Conway 
et al., 2012). This software allows us to evaluate the contamination from mouse DNA and 
to “clean-up” our samples. Before applying the Xenome software to our samples, we tested 
it by performing a calibration curve test. In particular, we spiked-in mouse reads into 
human reads at different percentages and applied the Xenome software. We observed that 
the calculated contamination was almost equal to that expected from the spike-in ratios; the 
calibration curve is a straight line with an intercept equal to 0.03 and a slope equal to 0.99 
(Figure 13). 
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Figure 13. Xenome Calibration Curve. We used the Xenome software to evaluate the potential 
contamination of mouse DNA within human samples. We spiked-in mouse reads, downloaded 
from SRA (Sequence Read Archive), into human reads of the primary tumour at different 
percentages. We then calculated the mouse contamination with the Xenome software. On the X-
axis, percentage of expected mouse contamination within human reads. On the Y-axis, percentage 
of calculated mouse contamination (number of reads flagged as mapping on the mouse genome by 
the Xenome software over the total number of reads) within human reads. 
Applying this additional filtering step to the standard WES analysis pipeline, we detected a 
mouse contamination in the sequencing reads of ~3% in the PDX sample and ~21% in 
PDX-derived mammosphere sample. Accordingly, we retained only those reads mapping 
to the human genome or to both the human and mouse genomes. We then realigned these 
reads against the human genome and called the variants again (Table 1 and Table 2). 
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Table 1. Comparison of Alignment Statistics of WES profiles of PDX and PDX-derived Mammospheres 
before and after Xenome filtering. 
Mapped Reads 
(%) 
Median 
Depth of 
Coverage 
(base) 
Coverage 
(>=20X) 
Unique Reads 
(%) 
On Target 
Reads (%) 
Before After Before After Before After Before After Before After 
PDX 92.5 97.8 119 118 97.4 97.3 96.0 96.2 79.0 79.1 
PDX-derived 
Mammospheres 68.3 92.6 89 106 95.6 96.9 95.1 94.0 79.3 75.3 
Table reports the percentage of aligned reads, median depth of coverage, bases with coverage ≥ 20X, uniquely 
aligned reads and on target reads, before and after Xenome filtering (Before and After in the table). 
Table 2. Comparison of somatic variant calling of PDX and PDX-derived Mammospheres before and after Xenome filtering. 
Frequency 1% Frequency 5% Frequency 10% Frequency 15% Frequency 20% 
Before After Before After Before After Before After Before After 
PDX 276145 115668 69038 12438 24107 5587 10343 3428 5619 2415 
PDX-derived Mammospheres 599716 105482 377350 15408 259016 6906 184608 4377 135668 3214 
Somatic variants were called using the VarScan2 software. We used different frequency thresholds to call somatic mutations (1-5-10-15-
20%), before and after Xenome filtering. 
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Despite filtering out many murine reads, we were able to obtain comparable WES profiles 
in all the samples analysed (primary tumour, primary tumour-derived mammospheres, 
PDX, PDX-derived mammospheres and blood) in terms of total aligned reads (93-98%), 
uniquely aligned reads (93-96%), on target reads (76-79%) and coverage (92-98% with 
coverage ≥ 20X) (Figure 14A). However, we did observe a lower median depth of 
coverage of aligned reads in samples with lower numbers of cells (primary tumour-derived 
mammospheres and PDX-derived mammospheres) compared with the other samples 
(Figure 14B). This might be a result of the lower heterogeneity of cells in mammosphere 
samples compared with primary tumours and PDXs, or a technical problem due to the 
lower amount of cells and therefore to a lower enrichment of some exonic regions. 
Although the median depth of coverage in mammosphere samples was sufficient to call 
variants, to overcome this problem in future experiments it might be possible either to 
increase the size of the mammosphere culture or to modify the incubation time of the 
WGA step. 
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Figure 14. Alignment statistics of WES experiments of the analysed samples. WES 
experiments were performed using an Illumina HiSeq2000 instrument on the primary tumour, 
primary tumour-derived mammospheres, PDX, PDX-derived mammospheres and blood samples. 
A Xenome filtering step was applied to PDX and PDX-derived mammosphere samples. Reads 
were aligned using bwa software and statistics were performed by custom R pipeline. A) 
Percentage of aligned reads (based on raw number of reads), uniquely aligned reads, on target reads 
and bases with coverage ≥ 20X (based on number of aligned reads). Coloured bars indicate 
different samples. B) Median depth of coverage: on Y-axis the value of the median depth of 
coverage; on X-axis the analysed samples. 
1.4. Control for Cross Contamination Germline Variation Analysis 
To assess the level of cross contamination of the DNA samples analysed with other 
unrelated DNA samples, as recently reported in a study on human DNA samples (Jun et 
al., 2012), we identified germline variations (GVs) in all tumour samples. We compared 
GVs of primary tumour-derived mammospheres and PDX-derived samples with GVs of 
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the primary tumour. In all cases, we obtained a concordance in GVs of at least 90%. As a 
negative control, we also compared GVs of our samples with GVs of an unrelated healthy 
individual and obtained an overlap of 0.7%. Based on these results, we concluded that our 
samples were derived from the patient being analysed and that the level of cross-
contamination was zero. 
 
2. Mutational Profile Analysis 
Using the mutational profiles of the matched primary tumour-PDX-mammosphere samples 
described above, we performed a series of analyses in an attempt to distillate patterns of 
mutations that could be informative either in terms of cancer relevant mutations or 
mutations related to CSCs.  
Our analyses were conducted according the following workflow: 
• Comparison of the mutational profile of primary tumour-derived mammospheres 
with that of the bulk primary tumour to identify mutations that were either 
“common” between the two samples or “enriched” in primary tumour-derived 
mammospheres compared to the primary tumour. 
• Comparison of the mutational profile of primary tumour-derived mammospheres 
with that of the PDX to identify mutations shared between the two samples, but 
undetectable within the primary tumour due to the detection limit of WES. 
• Analysis of the behaviour of the mutations identified in the comparison between 
primary tumour-derived mammospheres and the primary tumour with respect to the 
mutational profile of PDX and PDX-derived mammospheres.  
• Analysis of the behaviour of the mutations identified in the comparison between 
primary tumour-derived mammospheres and PDX with respect to the mutational 
profile of PDX-derived mammospheres.  
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We also tested the significance of the overlapping mutations. Finally, we performed WES 
with an orthogonal sequencing technology (Ion Torrent platform) to validate the identified 
mutations. 
2.1. Identification of Shared and Enriched Mutations 
The analyses described above allowed the identification of mutations that are either 
common to all the different samples or enriched in the primary tumour-derived 
mammosphere or PDX samples compared with the primary tumour. The shared mutations 
would have appeared in the initial population of cells, be responsible for the tumour onset 
and be present in nearly all cells of the tumour. They could represent a pool of variants that 
permitted the development of the primary tumour, i.e. the founder (or so-called “truncal”) 
somatic mutations, and would be expected to have a high frequency in all the matched 
samples. In addition, somatic mutations with low frequency shared between all samples 
may represent non-founder somatic mutations that appeared late in the evolution of the 
tumour and were selected for in a subpopulation of tumour cells.  
In contrast, the set of mutations enriched or appeared de novo in mammospheres or 
in the PDX sample compared with the primary tumour (i.e. mutations present at a lower 
frequency or undetectable in the primary tumour, respectively) could be part of the genetic 
make-up of rare sub-clones of cells dispersed within the bulk tumour population. Thus, 
such mutations would be diluted in the context of the molecular heterogeneity of the entire 
tumour mass and would be detected either at very low frequency or be undetectable by 
NGS in the primary tumour, due to the technical limitation of the deep sequencing 
technology. The identification of such enriched/ appeared de novo mutations is compatible 
with the idea of the existence of sub-clones of cells that harbour private somatic mutations 
that represent the driving force of tumour progression and metastasis formation. 
For the identification of mutations in the different samples, we used the somatic 
command of VarScan2 (Koboldt et al., 2012). Since VarScan2 permits the user to set the 
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minimum variant frequency to call and report a variant, we used different thresholds: 1%, 
5%, 10%, 15% and 20% (default value). Overall, we observed comparable numbers of 
mutations in the matched tumour samples, i.e. the primary tumour, PDX and 
corresponding mammosphere cultures (~20,000 mutations at 5% of frequency threshold; 
Figure 15). 
Since our aim was to identify “rare” mutations with a biological and functional role 
in CSCs and in the tumour, and to minimize the number of false positives, we focused our 
attention on mutations called at 5% frequency threshold that were exonic and non-
synonymous.  
 
Figure 15. Number of somatic variants identified by VarScan2 of analysed samples. WES 
reads obtained from the matched tumour samples were analysed using VarScan2 software to 
identify somatic variants. Different frequency thresholds were used to call somatic mutations 
(Frequency 1-5-10-15-20%). On the Y-axis, number of detected mutations. On the X-axis, the 
analysed samples.  
 
By the independent comparison of the mutational profile of the primary tumour-derived 
mammospheres with that of the primary tumour and PDX, we classified the called 
mutations into two main groups according to how they were shared between the different 
samples: 
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1. “Primary tumour-shared” mutations, corresponding to those mutations shared
between the primary tumour and primary tumour-derived mammospheres (LIST1,
Table 3).
2. “Mammosphere- and PDX-shared” mutations, corresponding to those mutations
that were below the WES detection limit in the primary tumour but present in
primary tumour-derived mammospheres and PDX (LIST2, Table 4).
We also performed further analyses (described below in 2.2) by cross-comparing: i) 
mutations of LIST1 (shared between primary tumour-derived mammospheres and primary 
tumour) with the mutational profiles of PDX and PDX-derived mammospheres; ii) 
mutations of LIST2 (shared between primary tumour-derived mammospheres and PDX 
compared to primary tumour) with the mutational profile of PDX-derived mammospheres. 
These analyses led to the identification of mutations shared across all the samples (primary 
tumour, primary tumour-derived mammospheres, PDX, and PDX-derived 
mammospheres), which likely represent “founder” or “truncal” mutations maintained 
throughout the branching evolution of the tumorigenic process (LIST3, Table 5 in red). In 
contrast, the set of mutations shared between primary tumour-derived mammospheres and 
the PDX that were also found in the profile of PDX-derived mammospheres (described in 
2.3 below) are likely to represent mutations belonging to sub-clones of cells (likely CSCs) 
involved in tumour progression towards metastasis (LIST4, Table 5 in black). 
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Table 3. “Primary tumour-shared” mutations present in LIST1. 
Mutation 
Name Chr Position 
Ref 
Allele 
Var 
Allele 
Mutation Frequency 
in Primary Tumour 
Mutation Frequency 
in Primary Tumour-
derived 
Mammospheres 
AEN 15 89173353 T G 8% 14% 
AKNA 9 117110115 T G 14% 7% 
ANKRD55 5 55412572 C T 54% 20% 
CHD3 17 7796815 G C 6% 12% 
CYP4F2 19 15989661 G A 6% 20% 
GALNT15 3 16250069 C T 42% 67% 
GOLGA6L1 15 22743086 C T 15% 19% 
GPATCH3 1 27226921 C A 5% 10% 
IRS1 2 227659828 T G 7% 8% 
KDM4E 11 94758846 A G 6% 19% 
KLRF1 12 9994450 G A 10% 14% 
KRT10_1 17 38975276 G C 8% 18% 
KRT10_2 17 38975277 A C 8% 17% 
KRT10_3 17 38975279 C T 7% 17% 
KRT10_4 17 38975280 T A 7% 17% 
KRTAP4-8 17 39254054 A T 14% 15% 
LHCGR 2 48982749 A G 5% 11% 
MUC6_1 11 1016585 G C 6% 7% 
MUC6_2 11 1030228 A C 25% 14% 
OR13C2 9 107367653 G C 6% 20% 
PABPC3_1 13 25670877 G A 8% 5% 
PABPC3_2 13 25670988 T G 7% 17% 
PABPC3_3 13 25671089 G T 18% 18% 
TAS2R19_1 12 11174467 A C 8% 13% 
TAS2R19_2 12 11174476 G A 11% 11% 
TAS2R30_1 12 11285909 G C 8% 10% 
TAS2R30_2 12 11285975 A T 6% 7% 
TAS2R30_3 12 11285978 A G 6% 6% 
TAS2R30_4 12 11286002 A C 5% 7% 
TAS2R30_5 12 11286024 T C 5% 7% 
TUBGCP3 13 113210444 G T 6% 6% 
Table reports annotations of LIST1 mutations: mutation name (composed of gene name alone when 
only one mutation is present in the corresponding gene or gene name_ordinal number when more 
than one mutation was present in the same gene), chromosomal coordinates, reference and variant 
alleles, mutation frequency in primary tumour-derived mammospheres and mutation frequency in 
primary tumour. Mutation frequency for each variant was calculated by VarScan2 software as the 
number of mutated reads over the coverage in each position. LIST1 is composed of mutation 
shared between primary tumour and primary tumour-derived mammospheres. 
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Table 4. “Mammosphere- and PDX-shared” mutations present in LIST2. 
Mutation 
Name 
Chr Position Ref 
Allele 
Var 
Allele 
Mutation 
Frequency in 
Primary 
Tumour 
Mutation 
Frequency in 
Primary Tumour-
derived 
Mammospheres 
Mutation 
Frequency 
in PDX 
ACOT1 14 74004547 C T ND 16% 12% 
AMOTL1 11 94592720 C T ND 13% 5% 
GOLGA6L1 15 22743398 T C ND 25% 17% 
GRIA3 X 122336604 C G ND 8% 8% 
MAL2 8 120220749 A C ND 7% 6% 
MUC4_1 3 195515470 T G ND 13% 14% 
MUC4_2 3 195515459 C T ND 21% 20% 
MUC4_3 3 195515449 A T ND 29% 29% 
OR13C2 9 107367674 G A ND 20% 25% 
PABPC3 13 25670907 C A ND 5% 7% 
RETSAT_1 2 85570849 C T ND 44% 12% 
RETSAT_2 2 85570857 G A ND 47% 10% 
USP20 9 132630666 A T ND 33% 17% 
ZNF28 19 53303182 T C ND 8% 5% 
Table reports annotations of LIST2 mutations: mutation name (composed of gene name alone 
when present only one mutation for the corresponding gene and gene name_ordinal number when 
more than one mutation was present for the same gene), chromosomal coordinates, reference and 
variant alleles, mutation frequency in primary tumour, mutation frequency in primary tumour-
derived mammospheres and mutation frequency in PDX. Mutation frequency for each variant was 
calculated by VarScan2 software as the number of mutated reads over the coverage in each 
position. ND = not detectable by WES. LIST2 is composed of mutations that were not detectable 
in the primary tumour, but present in primary tumour-derived mammospheres and PDX. 
66	
Table 5. Candidate “founder” mutations present in LIST3 (in red) and candidate CSC mutations present in LIST4 (in black). 
Mutation 
Name 
Chromosome Position 
Ref 
Allele 
Var 
Allele 
Mutation Frequency 
in Primary Tumour 
Mutation Frequency in 
Primary Tumour-
derived Mammospheres 
Mutation 
Frequency in 
PDX 
Mutation 
Frequency in 
PDX-derived 
Mammospheres 
AKNA 9 117110115 T G 14% 7% 19% 11% 
ANKRD55 5 55412572 C T 54% 20% 48% 56% 
GALNT15 3 16250069 C T 42% 67% 42% 53% 
PABPC3_3 13 25671089 G T 18% 18% 9% 19% 
ACOT1 14 74004547 C T ND 16% 12% 18% 
MUC4_2 3 195515459 C T ND 21% 20% 17% 
PABPC3 13 25670907 C A ND 5% 7% 6% 
RETSAT_1 2 85570849 C T ND 44% 12% 21% 
RETSAT_2 2 85570857 G A ND 47% 10% 26% 
Table reports annotations of LIST3 and LIST4 mutations: mutation name (composed of gene name alone when only one mutation is present in the 
corresponding gene and gene name_ordinal number when more than one mutation is present for the same gene), chromosomal coordinates, reference 
and variant alleles, mutation frequency in primary tumour-derived mammospheres, mutation frequency in primary tumour, mutation frequency in 
PDX and mutation frequency in PDX-derived mammospheres. Mutation frequency for each variant was calculated by VarScan2 software as the 
number of mutated reads over the coverage in each position. In red: mutations that were present in all four analysed samples, the founder mutations 
(LIST3); in black: mutations enriched in primary tumour-derived mammospheres, PDX and PDX-derived mammospheres (LIST4). ND = Not 
Detectable. 
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To verify the quality and significance of these mutations within the context of our 
experimental design, we manually checked a representative pool for each list that was: i) 
supported by at least two reads, one in forward and one in reverse; ii) present in at least 
two samples; iii) present in the normal blood sample with a frequency ≤ 5%. We did not 
exclude mutations annotated with a dbSNP entry, due to the fact that some somatic point 
mutations present in dbSNP database should not be excluded a priori as naturally 
occurring in the human genome because they have been experimentally associated with 
cancer (Jung et al., 2013). This manual control enabled us to verify that mutations in 
LIST1, LIST2, LIST3 and LIST4 were supported by good quality data in terms of 
supporting reads and coverage.  
To evaluate the significance of our gene lists, we compared the number of 
mutations in our lists with those present in random lists (LIST1_rand, LIST2_rand, 
LIST3_rand and LIST4_rand). We observed that our lists of genes showed a different 
distribution compared with the random lists (Figure 16A-D). We also tested the differences 
using the phyper function of R for LIST1 and LIST2, obtaining a p-value < 0.001 for both 
lists. The analysis indicated that shared mutations were not due to random mutational 
events, but rather they were the result of positive evolutionary selection. Thus, these 
mutations represent good candidates for the identification of cancer-relevant mutations 
involved in disease onset and progression, and therefore could be considered mutations for 
further analysis. 
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Figure 16. Comparison of our lists of mutations with random lists of mutations. Histograms 
showing the distribution of random overlaps in the four groups of mutations: LIST1, LIST2, LIST3 
and LIST4. Y-axis: the number of random sets of overlapping mutations. X-axis: the number of 
overlapping mutations. The dashed red line represents the number of mutations present in our lists. 
A) LIST1: primary-shared mutations present in the primary tumour and the primary tumour-
derived mammospheres; B) LIST2: mammosphere-PDX-enriched mutations present in primary
tumour-derived mammospheres and PDX; C) LIST3: truncal mutations present in primary tumour,
primary tumour-derived mammospheres, PDX and PDX-derived mammospheres; D) LIST4:
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mammospheres- PDX- and PDX-derived mammospheres enriched mutations present in, primary 
tumour-derived mammospheres, PDX and PDX-derived mammospheres. 
2.2. Identification of Candidate Founder Mutations 
As mentioned above, in an attempt to identify candidate founder mutations, we assessed 
the presence of mutations shared between the primary tumour and primary tumour-derived 
mammospheres (mutations comprised in LIST1) in the PDX and in the PDX-derived 
mammospheres. Among the 31 variants common to primary tumour and primary tumour-
derived mammospheres, 11 were also present in the PDX, and 4 of these 11 mutations, 
were also present in the PDX-derived mammospheres (LIST3, Table 5, in red). 
We reasoned that the 11 mutations shared between the primary tumour, primary 
tumour-derived mammospheres and PDX could represent a cluster of mutations of key 
importance for the tumorigenic process. Indeed, we note that 4 of these mutations were 
also conserved in PDX-derived mammospheres arguing that they were positively selected 
for during tumour formation in a host organism. Notably, only two mutations, the 
ANKRD55 and the GALNT15 mutations, could be considered as founder mutations as they 
appeared at high frequency in all analysed samples. Based on results from the cross-
comparison of the different mutational profiles, we concluded that our approach was able 
to identify a minimal set of mutations with a likely driver function in tumour onset and 
expansion: the AKNA, the ANKRD55, the GALNT15 and the PABPC3_3 mutations 
(LIST3, Table 5, in red). 
The AKNA gene (AT-hook-containing transcription factor), whose protein product 
is a transcription factor that activates the expression of CD40 and its ligand CD40L, has 
been described to be a cervical cancer susceptibility gene (Martinez-Nava et al., 2015). 
Moreover, nucleotide variations in this gene have been identified in relapsed tumours of 
children affected by high hyperdiploid acute lymphoblastic leukaemia (Chen et al., 2015). 
The ANKRD55 (ankyrin repeat domain-containing protein 55) gene is still 
uncharacterized in terms of function and implication in cancer. 
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The GALNT15 (polypeptide N-acetylgalactosaminyltransferase 15) gene encodes a 
protein member of the pp-GalNAc-T family, which is involved in the initiation of mucin-
type O-glycosylation. The GALNT15 gene has a similar expression pattern to MUC5AC 
and is able to transfer to MUC5AC up to seven GalNAc residues (Cheng_et_al-2004-
FEBS_Letters). The function of GALNT15 in cancer is still uncharacterized.  
The PABPC3 (poly(A)-binding protein cytoplasmic 3) gene encodes a protein 
involved in poly(A) tail of mRNAs. PABPC3 implication in cancer has not been 
characterized yet.  
In conclusion, of the 4 identified genes harbouring candidate founder mutations, 
only the AKNA gene has been demonstrated to be associated with cancer. Therefore, 
functional validation of the other 3 genes is warranted to demonstrate their possible 
involvement in cancer. 
2.3. Identification of Candidate CSC-specific Mutations 
CSCs are very rare cells within the primary tumour and therefore mutations present in the 
CSC compartment are predictably very difficult to identify when performing deep 
sequencing on the primary tumour. Hence, in an attempt to detect candidate CSC-specific 
mutations, we focused our attention on variants that were enriched in primary tumour-
derived mammospheres or in the PDX compared with the primary tumour. In particular, 
we classified as “enriched” those mutations that appeared in the primary tumour-derived 
mammospheres or in PDX with a frequency of at least 5% higher than that observed in the 
primary tumour. 
We identified 14 mutations, within LIST1 mutations, that, although detectable in 
the primary tumour, were enriched in primary tumour-derived mammospheres (AEN, 
CHD3, CYP4F2, GALNT15, GPATCH3, KDM4E, KRT10_1, KRT10_2, KRT10_3, 
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KRT10_4, LHCGR, OR13C2, PABPC3_1, TAS2R19_1). Of these 14 mutations, only 1, 
OR13C2, was also present and enriched in the PDX (Figure 17), while additional 4 
mutations (LHCGR, PABPC3_1, TAS2R19_1 and GALNT15) were present in the PDX, but 
not enriched (i.e., with a frequency in the PDX comparable to that observed in the primary 
tumour). 
From the comparative analysis of the mutational profiles of the primary tumour, 
primary tumour-derived mammospheres and PDX, we were therefore able to characterize a 
first set of 5 mutations (the OR13C2, LHCGR, PABPC3_1, TAS2R19_1 and GALNT15 
mutations mentioned above), which were common to the primary tumour and 
mammospheres, but also enriched in mammospheres and maintained in the PDX 
outgrowth. We argue that these mutations are harboured in sub-clones of cells endowed 
with a unique tumorigenic ability and therefore operationally classifiable as CSCs, a 
hypothesis in keeping with the observation that these mutations are part of the molecular 
profiles of the mammospheres and of the PDX derived from the primary tumour. 
We also noted that the GALNT15 mutation, besides being shared and expressed at 
high frequency across all the samples analysed, was further enriched in primary tumour-
derived mammospheres and PDX-derived mammospheres. We therefore speculated that 
this mutation could represent a lesion characteristic of the original CSC sub-clone present 
from the beginning of, and possibly responsible for, the tumorigenic process.  
In contrast, the 14 mutations enriched in primary tumour-derived mammospheres 
and PDX compared to the primary tumour counterpart (LIST2), likely constitute a set of 
mutations present in sub-clones of cells with a putative CSC activity, which appeared in 
the course of tumorigenesis as a consequence of genomic instability and became 
“dominant” in the evolutionary history of the primary tumour. 
In our analysis, we also identified a set of mutations that were shared between 
primary tumour-derived mammospheres and PDX, and appeared de novo in these samples 
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compared to the primary tumour (MAL2, GRIA3, ZNF28, AMOTL1, MUC4_1, MUC4_3, 
OR13C2, GOLGA6L1, USP20, PABPC3, MUC4_2, RETSAT_1, RETSAT_2 and ACOT1) 
(see LIST2 and Figure 18). We reasoned that the appearance of these mutations may be 
due to the existence of very rare sub-clones of cells, likely endowed with CSC activity, that 
became predominant in the short proliferative history of the primary tumour-derived 
mammospheres and of the PDX. In keeping with this hypothesis, we found that, in the set 
of mutations shared between primary tumour-derived mammospheres and PDX, it was 
possible to identify 5 mutations (PABPC3, MUC4_2, RETSAT_1, RETSAT_2 and ACOT1) 
(LIST4, Table 5, in black) common to PDX-derived mammospheres, arguing that these 
mutations likely represent candidate CSC-specific mutations. 
In conclusion, the bulk of our results indicate the existence of sub-clones of tumour 
cells that can harbour either shared (mutations comprised in LIST1) or private (mutations 
comprised in LIST4) mutations, which likely reflect set of mutations present in sub-clones 
of cells endowed with stemness activity. We also speculated that the frequency of these 
CSC sub-clones in the bulk tumour mass might be a function of their order of appearance 
throughout the evolutionary history of the tumour or of the specific molecular mechanisms 
controlling the dynamics of CSC expansion. Regardless, mutations harboured in rare sub-
clones of cells would appear at very low frequency or be undetectable by NGS in the 
primary tumour, due to the technical limitation of the deep sequencing technology. 
Together, these data indicate that our approach of performing WES on matched 
primary tumour, PDX and mammosphere samples is a suitable strategy for identifying rare 
mutations that are expressed at very low levels in the primary tumour, but become enriched 
during mammosphere or xenograft formation due to their presence in cells featuring CSC 
activity. These mutations could represent candidate driver mutations that are important in 
tumour onset and progression, including evolution towards metastasis. 
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Figure 17. Mutations in LIST1 with a higher frequency in primary tumour-derived mammospheres, PDX and PDX derived-mammospheres compared with 
the primary tumour. Mutations that were found to be enriched in terms of frequency in primary tumour-derived mammospheres and/or in the PDX and PDX-derived 
mammospheres compared with the primary tumour. Y-axis: frequency of detected mutations. X-axis: the mutated genes - different mutated positions within the same 
gene are reported as GeneName_#. 
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Figure 18. Mutation of LIST2 with a higher frequency in primary tumour-derived mammospheres, PDX and PDX derived-mammospheres compared with 
the primary tumour. Mutations that were found to be enriched in terms of frequency in primary tumour-derived mammospheres, in the PDX and PDX-derived 
mammospheres compared with the primary tumour. Y-axis: frequency of detected mutations. X-axis: the mutated genes - different mutated positions within the same 
gene are reported as GeneName_#. 
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2.4. Validation of Candidate CSC-specific Mutations by Ion Torrent WES 
To validate our results from the WES analysis using the Illumina platform, we decided to 
perform WES experiments applying an independent sequencing technology, namely the 
Ion Torrent platform. We therefore performed WES of WGA-DNA of the primary tumour, 
primary tumour-derived mammospheres, PDX, PDX-derived mammospheres and blood 
samples using the Ion Torrent sequencing platform.  
With the idea to validate CSC-specific mutations that are part of sub-clones of cells 
characterized by CSC activity, we focused our analyses on mutations enriched in LIST1 
and present in LIST2. Within enriched mutations in LIST1, we were able to confirm only 
two of them: GALNT15 and OR13C2. Despite a coverage >20X, the GPATCH3, LHCGR, 
KDM4E, PABPC3_1, AEN and CHD3 mutations failed to be confirmed by Ion Torrent. In 
addition, the other mutations (TAS2R19_1, KRT10_1, KRT10_2, KRT10_3, KRT10_4 and 
CYP4F2) lacked sufficient coverage (<20X) in the Ion Torrent experiments (Table 7). 
Of the mutations in LIST2, we were able to confirm mutations in the ACOT1, 
OR13C2 and RETSAT genes (both mutations), which all had a frequency higher than 10% 
in primary tumour-derived mammospheres, PDX and PDX-derived mammospheres. All 3 
MUC4 mutations lacked sufficient coverage in the Ion Torrent analysis, with only a few 
reads (<20) at the mutated position, and therefore could not be confirmed. Instead, the 
AMOTL1, PABPC3 and ZNF28 mutations were not present in the Ion Torrent experiment 
despite a coverage >20X in primary tumour-derived mammospheres, PDX and PDX-
derived mammospheres (Table 6). 
A possible explanation for this discrepancy between results from Illumina and Ion 
Torrent may lie in the different sequencing chemistries implemented in the two systems. 
Although we obtained less aligned reads in the Ion Torrent WES compared to the Illumina 
WES, the on target reads were higher in the Ion Torrent WES compared to the Illumina 
WES. In addition, while the mean depth of coverage and coverage >20X for the primary 
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tumour, primary tumour-derived mammospheres and PDX were comparable between 
Illumina and Ion Torrent WES, they were sub-optimal in the Ion Torrent analysis 
compared to the Illumina analysis for the PDX-derived mammospheres (Table 7). Hence, 
we were unable to obtain similar mutational profiles for the same sample using the two 
different sequencing approaches.  
Based on these considerations, we decided not to exclude a priori from further 
analyses those mutations that were not validated by Ion Torrent. Hence, we decided to 
characterize the enriched mutated genes in both primary tumour-derived mammospheres 
and the PDX compared with the primary tumour (in both LIST1 and LIST2) found in the 
Illumina experiments in terms of functional involvement in cancer.
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Table 6. Candidate CSC-specific mutations identified by Illumina and Ion Torrent WES. 
Illumina WES Ion Torrent WES 
Mutation Name List Chr Position 
Primary 
tumour-derived 
Mammospheres 
PDX PDX-derived Mammospheres 
Primary 
tumour-derived 
Mammospheres 
PDX PDX-derived Mammospheres 
AEN LIST1 15 89173353 P NP NP NP NP NP 
CHD3 LIST1 17 7796815 P NP NP NP NP NP 
CYP4F2 LIST1 19 15989661 P NP NP NP NP NP 
GALNT15 LIST1 3 16250069 P P P P P P 
GPATCH3 LIST1 1 27226921 P NP NP NP NP NP 
KDM4E LIST1 11 94758846 P NP NP NP NP NP 
KRT10_1 LIST1 17 38975279 P NP NP NP NP NP 
KRT10_2 LIST1 17 38975280 P NP NP NP NP NP 
KRT10_3 LIST1 17 38975276 P NP NP NP NP NP 
KRT10_4 LIST1 17 38975277 P NP NP NP NP NP 
LHCGR LIST1 2 48982749 P P NP NP NP NP 
OR13C2 LIST1 9 107367653 P P NP P P P 
PABPC3_1 LIST1 13 25670988 P P NP NP NP NP 
TAS2R19_1 LIST1 12 11174467 P P NP NP NP NP 
ACOT1 LIST2 14 74004547 P P P P P P 
AMOTL1 LIST2 11 94592720 P P NP NP NP NP 
GOLGA6L1 LIST2 15 22743398 P P NP NP NP NP 
GRIA3 LIST2 X 122336604 P P NP NP NP NP 
MAL2 LIST2 8 120220749 P P NP NP NP NP 
MUC4_1 LIST2 3 195515470 P P NP NP NP NP 
MUC4_2 LIST2 3 195515459 P P P NP NP NP 
MUC4_3 LIST2 3 195515449 P P NP NP NP NP 
OR13C2 LIST2 9 107367674 P P NP P P P 
PABPC3 LIST2 13 25670907 P P P NP NP NP 
RETSAT_1 LIST2 2 85570849 P P P P P P 
RETSAT_2 LIST2 2 85570857 P P P P P P 
USP20 LIST2 9 132630666 P P NP NP NP NP 
ZNF28 LIST2 19 53303182 P P NP NP NP NP 
The table reports the mutation names, the chromosomal coordinates and the presence of the mutation in the Illumina and Ion Torrent WES profiles of the 
primary tumour-derived mammospheres, PDX and PDX-derived mammospheres samples for candidate CSC-specific mutations. P= present; NP = not present. 
In red: mutations considered for further analysis. 
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Table 7. Comparison of Illumina and Ion Torrent Alignment Statistics. 
Illumina WES Ion Torrent WES 
Number of 
Mapped 
Reads 
Reads On 
Target 
(%) 
Mean Depth of 
Coverage 
(base) 
Coverage 
>20X
(%)
Number of 
Mapped 
Reads 
Reads On 
Target 
(%) 
Mean Depth of 
Coverage 
(base) 
Coverage 
>20X
(%)
Primary Tumour 125,386,838 78 136 98 31,624,977 86 82 89 
Mammospheres 111,268,203 76 67 92 41,617,735 84 102 71 
PDX 107,663,534 79 119 97 22,289,307 90 60 84 
PDX-derived 
Mammospheres 82,380,904 79 89 95 8,615,822 84 21 39 
Blood 142,144,133 78 148 98 30,934,336 92 84 90 
WES experiments were performed using an Ion Torrent instrument on the primary tumour, primary tumour-derived mammospheres, PDX, PDX-derived 
mammospheres and blood samples. Number of total mapped reads, percentage of on target reads, mean depth of coverage and bases with coverage > 20X 
are reported. 
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2.5. Determination of Functional Impact of Candidate CSC-specific Mutations 
To understand the potential functional impact of our candidate CSC-specific mutations, we 
first determined whether the amino acid changes resulting from the identified mutations in 
our candidate CSC-specific genes were within particular functional domains of the 
corresponding proteins. To this end, we used UniProt website (http://www.uniprot.org/) 
and cBioPortal website (http://www.cbioportal.org/) to map the chromosomal coordinates 
of the mutated positions onto protein coordinates. We also used the TCGA breast invasive 
carcinoma dataset to screen for mutations previously identified in our candidate CSC-
specific genes in breast cancer. 
We found that the mutations present in GOLGA6L1, MAL2, MUC4, PABPC3, 
RETSAT and ZNF28 do not fall within specific protein domains (Figure 19), while the 
mutations in ACOT1, AMOTL1, GRIA3, OR13C2 (both two mutations present in the two 
lists) and USP20 were present in specific protein domains (Figure 20). In particular, the 
ACOT1 mutation is in the Acyl-CoA thioester hydrolase domain of the protein. The 
AMOTL1 mutation is in the Angiomotin domain. The GRIA3 mutation is in the ANF 
receptor ligand domain. Both OR13C2 mutations fall within the transmembrane domain of 
the protein. Finally, the USP20 mutation is in the ubiquitin carboxyl-terminal hydrolase 
domain.  
Notably, within the COSMIC database v77, the same mutations of the ACOT1, 
GOLGA6L1, MUC4, PABPC3, RETSAT and ZNF28 genes identified in our analysis were 
present, although not in breast cancer tissue. See Table 8 for detailed COSMIC annotations 
of these mutations. 
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Table 8. COSMIC annotation of candidate CSC-specific mutations. 
Mutation Name Tumour Tissue COSMIC ID 
ACOT1 Prostate COSM5423118 
GOLGA6L1 
Large Intestine 
Pancreas 
Upper Aerodigestive Tract 
COSM4443866 
MUC4_1 
Biliary Tract 
Large Intestine 
Prostate 
COSM5463888 
MUC4_2 Bile Duct 
Head And Neck 
COSM4322884 
MUC4_3 
Biliary Tract 
Central Nervous System 
Cervix 
Eye 
Hematopoietic And Lymphoid Tissue 
Kidney 
Large Intestine 
Liver 
Prostate 
Upper Aerodigestive Tract 
COSM1131502 
PABPC3 
Kidney 
Large Intestine 
Lung 
Upper Aerodigestive Tract 
COSM3773669 
RETSAT_1 
Biliary Tract 
Liver  
Thyroid 
COSM3746549 
RETSAT_2 
Biliary Tract 
Haematopoietic And Lymphoid Tissue 
Liver 
Thyroid 
COSM3746550 
ZNF28 
Large Intestine 
Liver 
Pancreas 
COSM4286443 
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Figure 19. Positions of mutations relative to protein domains (Part1). Schematic structures of 
proteins encoded by candidate CSC-specific genes identified by Illumina WES (GOLGA6L1, 
MAL2, MUC4 PABPC3, RETSAT and ZNF28). The positions of known protein domains are 
indicated by coloured rectangles and the positions of mutations identified in our study or listed in 
the TCGA breast invasive carcinoma dataset are shown by dots. Pink dots represent the mutation 
identified in this study. Green dot represents missense mutations. Black dots represent nonsense 
mutations. Brown dots represent in-frame insertions. Y-axis: number of mutations present into 
TCGA breast invasive carcinoma dataset. X-axis: amino acid positions. Images were adapted from 
cBioPortal. 
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Figure 20. Positions of mutations relative to protein domains (Part2). Schematic structures of 
proteins encoded by candidate CSC-specific genes identified by Illumina WES (ACOT1, AMOTL1, 
GRIA3, OR13C2 and USP20). The positions of known protein domains are indicated by coloured 
rectangles and the positions of mutations identified in our study or listed in the TCGA breast 
invasive carcinoma dataset are shown by dots. Pink dots represent the mutation identified in this 
study. Green dot represents missense mutations. Black dots represent nonsense mutations. Brown 
dots represent in-frame insertions. Y-axis: number of mutations present into TCGA breast invasive 
carcinoma dataset. X-axis: amino acid positions. Images were adapted from cBioPortal. 
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To understand if the mutations have a functional impact on the expressed proteins, we used 
several website tools for prediction (the results of the predictive tools we used are reported 
in Table 9), including: 
• PROVEAN, which is based on two main steps. In the first one, PROVEAN collects
a set of homologous and distantly related sequences and clusters them by sequence
identity to obtain a supporting sequence set with the most similar sequence to query.
In the second step, a delta score (named also PROVEAN score), which is based on
the similarity matrix BLOSUM62, is calculated for each sequence of the supporting
set. If the PROVEAN score is smaller than or equal to a given threshold, the
variation is predicted as deleterious.
• SIFT that identifies homologous functional proteins, performs multiple sequence
alignment and calculates the probability for all 20 amino acids at query position.
Hence this probability is normalized by the most frequent amino acid to obtain a
scaled probability, which is used to classify the damaging potential of the
substitution.
• FATHMM, which is based on 10 feature groups to annotate variants from HGMD
(pathogenic dataset) and 1000 Genome Project (control dataset). These 10 groups
include 46-way sequence conservation, histone modifications, transcription factor
binding, open chromatin (based on DNase-Seq), 100-way sequence, GC-content,
open chromatin (based on FAIRE), transcription factor binding sites, genome
segmentation and footprints. FATHMM then integrates all these features using a
classifier based on multiple kernel learning (MKL) to score functional impact of all
variants.
• PolyPhen2, which extracts different sequence- and structure-based features to be
subjected to a probabilistic classifier, based on machine-learning method.
Sequence-based features encompass the occurrence of the substitution within a
specific site and the conservation of the substituted nucleotide in a family of
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homologous proteins. Structure-based parameters, which is related to the mapping 
of the variant amino acid either on known 3D structure or on 3D structure of 
homologous proteins, include accessible surface area, hydrophobic propensity and 
B-factor (index of atom mobility).
• Mutation Assessor , which is based on evolutionary conservation of the affected
amino acid in protein homologs. Mutation Assessor uses a multiple sequence
alignment to calculate a functional score. This score is a combination of
conservation score (conserved residues across the entire family) and specificity
score (conserved residues within each subfamily, but vary between subfamilies).
• CADD that integrates multiple annotations into one metric to all variants that
survived natural selection (present in the 1000 Genome Project catalogue; The
1000 Genomes Project Consortium, 2012) and to simulated mutations. To simulate
SNVs and INDELs, CADD applies a genome-wide simulator of de novo variations.
Then, CADD annotates each variant using the Ensembl Variant Effect Predictor
(VEP) (McLaren et al., 2010), containing information taken from i.e. GERP
(Cooper et al., 2005), phastCons (Siepel et al., 2005), Grantham (Grantham, 1974),
SIFT (Kumar et al., 2009) and PolyPhen (Adzhubei et al., 2013).
From Table 9, it is clear that it was not always possible to achieve a consensus among all 
the six predictors. Of note, FATHMM and CADD report a score of deleteriousness, and in 
particular, FATHMM considers as damaging all those mutations with a score >0.5. 
Although CADD developers do not indicate a defined score to assess the deleterious 
impact of the mutations, they suggest using 15 as a threshold. 
The mutation that consistently was predicted to have deleterious impact on protein 
structure and function was the RETSAT_1 mutation, which scored as damaging by all tools, 
except for Mutation Assessor, which predicted a medium impact. Instead, several 
mutations were predicted to be damaging by at least 4 tools, including RETSAT_2, 
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OR13C2 (LIST2) and ZNF28. While other mutations were predicted to be damaging by 
less than 4 tools, e.g. MAL2, GRIA3, MUC4_2, OR13C2 (LIST1) and USP20. In contrast, 
the ACOT1, AMOTL1, GOLGA6L1, MUC4_1, MUC4_3 and PABPC3 mutations were 
predicted not to have a deleterious impact on the protein structure and function according 
to all six tools, and thus their possible impact on protein structure and function is still 
unclear. 
In an attempt to assess the relevance of the candidate CSC-specific mutations to 
cancer in general and, in particular, to breast cancer, we performed a literature search. For 
the ACOT1, GOLGA6L1, OR13C2, PABPC3, RETSAT and ZNF28 genes no reports of an 
involvement in cancer were found in the literature. In contrast, for the AMOTL1, GRIA3, 
MAL2, MUC4 and USP20 genes a direct or indirect role in cancer has been previously 
described. 
In particular, the AMOTL1 (acyl-CoA thioesterase 1) gene encodes for a peripheral 
membrane protein that is a component of tight junctions. AMOTL1 mRNA has been 
identified as differentially expressed between ER- and ER+ breast cancer and AMOTL1 
protein has been shown to participate in EMT and stimulate breast cancer cell proliferation 
by inducing Src activity (Couderc et al., 2016).  
The GRIA3 (glutamate ionotropic receptor AMPA type subunit 3) gene, whose 
protein product is a subunit of the glutamate receptor family, is a downstream target of 
CUX1 (Cut Like Homeobox 1). CUX1 effects on tumour proliferation, survival and 
migration are mediated by GRIA3 in pancreatic cells in vitro and in vivo (Ripka et al., 
2010).  
The MAL2 (mal, T-cell differentiation protein 2) gene encodes a multi-span 
transmembrane protein belonging to the MAL proteolipid family. MAL2 mRNA has been 
shown to be significantly upregulated in pancreatic metastatic cell line compared with 
parent non-metastatic cells (Eguchi et al., 2013), and MAL2 protein is a heterologous 
86	
partner for TPD52-like proteins (Wilson et al., 2001), which are overexpressed in breast 
cancer (Shehata et al., 2008).  
The MUC4 (mucin 4) gene encodes an integral membrane glycoprotein that acts as 
a ligand for ERBB2 and has been shown to mask the Trastuzumab binding site, inducing 
Trastuzumab resistance both in vitro and in vivo (Elster et al., 2015). Reduced MUC4 
protein expression in invasive breast carcinoma is involved in tumour progression and 
correlates with increased tumour-infiltrating immune cells and promotes hyper-
methylation (Cho et al., 2015).  
The USP20 (ubiquitin specific peptidase 20, also called VDU2) gene encodes an 
ubiquitin specific protease that deubiquitinates hypoxia-inducible factor (HIF)-1 alpha 
causing an increased expression of HIF1α target genes and enhancing HIF1α mediated 
activities (i.e. angiogenesis, cell proliferation and metastasis) (Li et al., 2005). 
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Table 9. Functional impact prediction of candidate CSC-specific mutations. 
Mutation 
Name PROVEAN SIFT FATHMM PolyPhen2 
Mutation 
Assessor CADD 
OR13C2 
(LIST1) N T 0.13718 Poss Dam Low 11.75 
ACOT1 N T 0.22913 B Low 13.61 
AMOTL1 N T 0.38461 B Low 5.04 
GOLGA6L1 N T 0.00072 B Neutral 0.07 
GRIA3 Del Dam 0.02938 B NA 2.30 
MAL2 NA NA 0.82925 Poss Dam NA 21.50 
MUC4_1 N T 0.00119 B NA 0.00 
MUC4_2 N Dam 0.00475 Poss Dam NA 0.27 
MUC4_3 N T 0.00106 B NA 3.07 
OR13C2 
(LIST2) Del Dam 0.94326 B Medium 11.63 
PABPC3 N T 0.05858 B Neutral 0.94 
RETSAT_1 Del Dam 0.85171 Prob Dam Medium 29.50 
RETSAT_2 N T 0.84738 Poss Dam Medium 22.70 
USP20 N T 0.88918 B Neutral 4.79 
ZNF28 Del Dam 0.03656 Prob Dam Low 23.80 
Six prediction tools (PROVEAN, SIFT, FATHMM, PolyPhen2, Mutation Assessor and CADD) 
were used to predict the functional consequences of the candidate CSC-specific mutations. N = 
Neutral; T = Tolerated; B= Benign; Del = Deleterious; Dam = Damaging; Poss Dam = Possibly 
Damaging; Prob Dam = Probably Damaging. For FATHMM and CADD, values >0.5 and >15 
represent deleterious mutations, respectively. NA = result not available, in particular the prediction 
tool Mutation Assessor was not able to retrieve a protein structure for the MUC4 gene and the 
GRIA3 gene. 
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Discussion 
Over the past few years, our knowledge on the on the clinical and pathological 
heterogeneity of human breast cancers has considerably expanded. On the one hand, major 
molecular subtypes of breast cancer (Luminal-A, Luminal-B, Basal-like, HER2) have been 
recognized, which have become critical for addressing inter-tumour heterogeneity and for 
informing patient management in the clinical practice (Perou et al., 2000; Sorlie et al., 
2001). On the other, parallel sequencing studies have provided evidence that, like other 
solid tumours, breast cancers can also show varying degrees of intra-tumour heterogeneity, 
with the presence of subpopulations of cells with profound genomic and phenotypic 
differences (Cottu et al., 2008; Shah et al., 2009; Navin et al., 2010; Navin et al., 2011; 
Shah et al., 2012; Nik-Zainal et al., 2012). Remarkably, these differences can be detected 
either in the context of the bulk primary tumour and between the primary tumour and its 
metastasis (Torres et al., 2007; Ding et al., 2010). It is also becoming increasingly evident 
that the two models historically invoked to explain intra-tumour heterogeneity, i.e. the 
clonal evolution and the CSC model (Reya et al., 2001; Shackleton et al., 2009; Visvader, 
2011; Meacham and Morrison, 2013), are not necessarily mutually exclusive, at least for 
those tumours characterized by high levels of genomic instability (Torres et al., 2007; 
Kreso and Dick, 2014; Meacham and Morrison, 2013). In the clonal evolution model, the 
clone with the highest degree of fitness, due to the stochastic occurrence of genetic and 
epigenetic alterations, is selected for and outcompetes other possible clones in a spatial and 
temporal fashion according to a Darwinian evolutionary process (Merlo et al., 2006; 
Gerlinger et al., 2012; Bedard et al., 2013). This scenario also applies to the acquisition of 
therapy resistance and metastatic ability by tumour cells (Marusyk and Polyak, 2010; 
Greaves and Maley, 2012). Therefore, in the clonal evolution model, tumour eradication 
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can be achieved only when the entire subset of cells showing similar genetic make-up and 
phenotypical behaviour are targeted by therapies. 
In contrast, the CSC model holds that tumours, like normal tissues, are 
hierarchically organized and that, therefore, the nature of intratumoral heterogeneity is 
largely phenotypic. The hierarchical organization presupposes the existence of CSCs, 
either derived from malignant transformation of normal stem cells or from progenitors that 
have re-acquired stemness traits, which are responsible for the tumorigenic process, while 
giving origin to a progeny of non-tumorigenic and phenotypically heterogeneous 
progenitors (Reya et al., 2001; Dick, 2008; Clevers, 2011; Beck and Blanpain, 2013). From 
a therapeutic point of view, a corollary of this model is that tumour eradication can be 
achieved only when CSCs are eliminated (Creighton et al., 2009; Diehn et al., 2009; 
Bedard et al., 2013). As mentioned above, the clonal evolution and the CSC theory are not 
necessarily mutually exclusive, considering the possibility that, in tumours with high 
genetic instability, CSCs may also contribute to intra-tumour heterogeneity with the 
presence of CSC clones that are genetically heterogeneous (Cottu et al., 2008; Shah et al., 
2009; Navin et al., 2010; Navin et al., 2011; Shah et al., 2012; Nik-Zainal et al., 2012). The 
co-existence of genetically different CSC clones would, for instance, account for the co-
existence of multiple genetically distinct lineages of tumour cells typical of poly-genomic 
breast cancers (Navin et al., 2011; Shah et al., 2012). 
One important implication of the CSC model is that mutations putatively involved 
in the emergence and expansion of CSCs might be present at very low frequency and, 
especially in tumours with a high degree of genomic instability, “diluted” in the wide 
heterogeneous landscape of mutations progressively accumulated in the bulk progenitor 
population during the proliferative history of the tumour. In more general terms, 
distinguishing the true “driver” mutations of the tumorigenic process from the “passenger” 
mutations that represent a by-product of tumour development constitutes a major challenge 
in massive parallel sequencing studies. In this regard, recent studies have demonstrated 
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that it is possible to resolve the initial heterogeneity of the primary tumour by xenografting 
it into an immunocompromised host. In the original study from Ding et al. (Ding et al., 
2010), this approach resulted in the identification of mutations expressed at very low or 
even undetectable levels in the primary tumour, which were enriched in the mutational 
profile of the xenograft and also of the distant metastasis from the same breast cancer 
patient. These findings argue that in the relatively short proliferative history of the 
xenograft and metastatic outgrowths, it is possible to identify mutations with a likely driver 
role in the tumorigenic process.  
Based on these premises, we decided to perform a comparative analysis of a 
primary breast tumour and of its matched mammosphere and xenograft samples, based on 
the dual assumption that: i) the ability to generate mammospheres and to drive xenograft 
outgrowth resides in sub-clones of cells characterised by a unique tumorigenic ability; ii) 
the short proliferative history required for the formation of mammospheres and of the PDX 
should minimize the confounding effect of passenger lesions appearing as by-products of 
the intrinsic genomic instability of tumour cells. We therefore used NGS data derived from 
the analysis of the primary tumour and its matched mammosphere and PDX samples to 
identify a subset of mutations either shared or enriched in mammospheres and in the 
xenograft, which might represent driver mutations likely belonging to the profile of tumour 
cells with an intrinsic stemness ability. 
1. Optimisation of the WES Protocol
Before testing our hypothesis, we set out to optimise the protocol for the application of 
deep sequencing to samples composed of very few cells. To this end, we tested whether the 
DNA amplification step, the WGA technique, required to obtain sufficient DNA material 
from small amount of starting DNA, introduced any bias in the WES profiles. Therefore, 
we performed WES on gDNA and WGA-DNA from the same tumour test sample. After 
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the comparison of WES alignment and mutational profiles of gDNA and WGA-DNA, we 
established that the WGA did not introduce artefacts within the WES experiments. In 
particular, we obtained an overlap of variants of ~80% and comparable alignment statistics. 
Hence, we applied the WGA-WES strategy to our experimental samples: a primary breast 
tumour and matched primary tumour-derived mammospheres, composed mostly of early 
progenitors that are representative of the CSC compartment, PDX, PDX-derived 
mammospheres and blood samples. Starting from a limited amount of gDNA 
(approximately 10 ng/µl) and applying the WGA step to all experimental samples, we were 
able to perform a NGS analysis. This allowed us to compare the mutational profile of 
primary tumour-derived mammospheres with that of the primary tumour and also of the 
PDX and PDX-derived mammospheres.  
Furthermore, we have also implemented a bioinformatics strategy (based on the 
Xenome software), which allowed us to successfully eliminate mouse contamination 
within PDX-derived samples (PDX and PDX-derived mammospheres). This was necessary 
to reduce false positives when calling mutations and to obtain a reliable genetic profile of 
the PDX-derived samples. 
 
2. Identification of Candidate Founder Mutations 
By comparing the mutational profiles of primary tumour, primary tumour-derived 
mammospheres and PDX, we identified 11 mutations that were present in primary tumour, 
primary tumour-derived mammospheres and PDX, with a comparable mutation frequency 
among all analysed samples. We reasoned that this set of mutations most likely represents 
a cluster of founder genetic lesions required for the onset and progression of 
tumorigenesis. Supporting this idea, we found that 4 of these 11 mutations (AKNA, 
ANKRD55, GALNT15 and PABPC3_3 mutations, LIST3 in the Results) were also present 
in PDX-derived mammospheres, indicating a strong selective pressure towards the 
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maintenance of these mutations as a part of the genetic make-up of tumour sub-clones with 
high tumorigenic potential. We also noted that two mutations, ANKRD55 and GALNT15, 
are present in all samples at high frequency, further arguing for their role as “founder” (or 
“truncal”) mutations (De Grassi et al., 2014). These results indicate that the bulk tumour 
cells, due to their intrinsic genetic instability, may acquire distinct genetic profiles during 
tumour formation and that shortening the proliferative history of the tumorigenic process, 
as recapitulated in the xenograft or mammosphere setting, is instrumental to identify 
mutations that are likely to be the real “drivers” of tumour growth. 
Of note, the 4 mutated genes carrying the 4 mutations common to all samples have 
never been previously described as relevant to cancer, with the exception of the AKNA 
gene, which has been described to have a function in cervical cancer (Martinez-Nava et al., 
2015) and leukaemia (Chen et al., 2015).  
3. Identification of Candidate CSC-specific Mutations
From the comparative analysis of the primary tumour and mammospheres, it was possible 
to identify 14 mutations that were enriched in primary tumour-derived mammospheres, 
compared to the primary tumour (mutations present within LIST1 in the Results). Of note, 
one of these mutations (OR13C2, LIST1 in the Results) was also enriched in the PDX, 
while only the GALNT15 mutation was present also in PDX-derived mammospheres. We 
also performed a comparative analysis of the mutational profile of primary tumour-derived 
mammospheres with that of the PDX. Remarkably, by this approach, we identified 14 
overlapping mutations (LIST2 in the Results) that were not detectable within the bulk 
population of the primary tumour. Thus, direct NGS analysis of mammospheres could help 
to find a core-component of cancer-relevant genes that were not immediately identifiable 
in the mutational profile of the primary tumour. The most straightforward explanation is 
that the set of mutations appeared de novo in mammospheres or in the PDX compared to 
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the primary tumour likely belong to sub-clones of CSCs scarcely represented in the bulk 
tumour mass. These mutations would not be identified by NGS because of the detection 
limit of the procedure. Arguing for the actual relevance of some of these mutations to the 
ability of CSCs to drive tumorigenesis, we found that 5 of these 14 LIST2 mutations were 
maintained in PDX-mammospheres. 
We were able to identify at least three mutated genes (AMOTL1, MAL2 and MUC4) 
whose involvement in breast cancer were also described in other independent studies. In 
particular, AMOTL1 gene was found upregulated in oestrogen receptor negative breast 
tumours and its protein level was negatively regulated by the direct interaction with tumour 
suppressor NF2. In addition, NF2 is able to induce AMOTL1 phosphorilation, which leads 
to AMOTL1 degradation in BC52 cells by increasing its binding to NEDD4 family of 
ubiquitin ligases (Couderc et al., 2016). In contrast, in normal endothelial cells, Choi and 
colleagues demonstrated that HECW2 E3 ligases was able to stabilize AMOTL1 through 
lysine 63-linked polyubiquitination and to increase its localization to junction area of 
human umbilical vein endothelial cells (Choi et al., 2016). Thus far, a complete and clear 
function of AMOTL1 ubiquitination is still missing and therefore a possible role of 
nucleotide mutations in the AMOTL1 gene in its interactions with Merlin and ubiquitin 
ligases. 
MAL2 protein is a heterologous partner of all three TPD52-like proteins (TPD52, 
TPD52L1 and TPD52L2) (Wilson et al,. 2001), and is overexpressed in metastatic 
pancreatic cell line compared to non-metastatic cells (Eguchi et al., 2013). In breast cancer 
MAL2 and TPD52-like genes were also found overexpressed (Shehata et al., 2008) 
indicating a potential oncogenic role of these genes. Additionally, Li and colleagues (Li et 
al., 2016) demonstrated that miR-34a overexpression significantly inhibited the expression 
of TPD52 and block invasion/migration phenotypes in breast cancer cells. Therefore, 
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analysis of miR-34a and TPD52 expression in the context of MAL2 mutations could 
eventually clarify the functional role of MAL2 in breast cancer.  
Finally, overexpression of MUC4 in breast cancer promotes metastasis formation 
by the disruption of cell-cell and cell-extracellular matrix interactions, preventing cell 
anoikis (Workman et al., 2009), and by the sustained expression of EGFR family proteins 
and β-catenin (Mukhopadhyay et al., 2013). Thus, characterization of the functional roles 
of the mutated forms of MUC4 gene in its overexpression may lead to the identification of 
its potential contribute to breast cancer formation and progression. 
Lastly, although the RETSAT gene has not been reported so far to be implicated in 
cancer, all the six predictive tools we used in our analysis have predicted a damaging role 
of the mutation we identified, which warrants further investigation of an eventual cancer 
role for the RETSAT gene.  
4. Limitations of Our Study Design
Although we obtained encouraging results, we are aware that our study may suffer from a 
number of limitations. Firstly, for obvious reasons, we could sequence only a fraction of 
the primary tumour from the patient, i.e. the amount of tissue available through the biopsy 
specimen that was destined to molecular studies. The possibility exists therefore that the 
molecular profile we have obtained from the biopsy specimen of the primary tumour might 
not be entirely representative of the entire collection of mutations of the bulk primary 
tumour mass. This scenario has been previously described in the work of Gerlinger and 
colleagues (Gerlinger et al., 2012) which showed the existence of a spatial intratumoral 
heterogeneity with the presence of private mutations present only in a few areas of the 
tumour in addition to mutations shared by most of the tumour areas analysed. 
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Another important point is that, if it is true that by the mutational profiling of 
mammospheres and PDX we have likely identified mutations belonging to sub-clones of 
cells endowed with stemness ability, it is difficult to predict whether these mutations are 
present in individual CSC clones or shared across more than one clone. In other words, if 
our approach revealed to be instrumental to deconvoluting tumour heterogeneity with the 
identification of mutations with a likely tumorigenic function, it does not allow understand 
whether multiple CSC clones co-exist in the bulk tumour mass, which appears to be the 
case of polygenomic tumours. 
5. Conclusion
We developed an experimental and bioinformatics strategy to identify candidate cancer-
relevant genes in breast cancer samples. We applied the WGA-WES protocol to matched 
primary tumour, mammosphere and PDX-derived samples. While the comparative analysis 
of a primary tumour with its matched xenograft has already been exploited as a strategy to 
deconvolute the heterogeneity of the primary tumour, the use of mammospheres derived 
from the primary tumour constitutes a novel approach allowing the identification of 
mutations with a likely relevance to the biology of CSC. The bulk of our results indicate 
the existence in the context of the primary tumour of sub-clones of cells that may harbour 
either shared and private somatic mutations likely at the basis of the masterplan of the 
tumorigenic process. Whether the shared and private mutations simply indicate the co-
existence of several heterogeneous CSC clones or their hierarchical organization according 
to a spatial or temporal evolutionary tree remains to be elucidated. 
6. Future plans
In the forthcoming future, we plan to extend the WGA-WES analysis of matched primary 
tumour, mammosphere and PDX samples to a set of additional breast tumours belonging to 
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different breast tumour subtypes. An important step in future studies will be the validation 
by targeted re-sequencing of the most relevant mutations found in our experimental model, 
using an alternative NGS platform (i.e. Ion Torrent or miSeq).  
We also plan to perform high resolution studies on candidate mutated genes to 
assess their functional relevance to CSC biology and to tumour progression and metastasis. 
To this aim, we plan to use strategies to over-express or silence candidate mutated genes in 
relevant model systems. The genes to be subjected to functional validation studies will be 
selected based on results from a preliminary analysis of a sizable cohort of human breast 
cancers. 
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